[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 46 of about 46
1. Seya T, Tanaka N, Shinji S, Shinji E, Yokoi K, Horiba K, Kanazawa Y, Yamada T, Oaki Y, Tajiri T: Case of rectal malignant melanoma showing immunohistochemical variability in a tumor. J Nippon Med Sch; 2007 Oct;74(5):377-81
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Case of rectal malignant melanoma showing immunohistochemical variability in a tumor.
  • We report on a patient with rectal malignant melanoma.
  • With the diagnosis of neuroendocrine carcinoma of the rectum, abdominoperineal resection was performed.
  • However, the final pathological diagnosis of the surgically resected specimen was malignant amelanotic melanoma of the rectum.
  • As preoperative pathological diagnosis showed rare rectal tumor, we measured the chemosensitivity of the rectal tumor using the collagen gel droplet-embedded culture drug sensitivity test (CD-DST) to determine the most appropriate chemotherapy regimen for the patient.
  • However, there were no anticancer drugs tested by CD-DST for malignant melanoma.
  • [MeSH-major] Biomarkers, Tumor / analysis. Melanoma / diagnosis. Neoplasm Proteins / analysis. Proto-Oncogene Proteins c-kit / analysis. Rectal Neoplasms / diagnosis
  • [MeSH-minor] Adult. Antigens, Neoplasm. Antineoplastic Combined Chemotherapy Protocols / pharmacology. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Digestive System Surgical Procedures. Drug Resistance, Neoplasm. Drug Screening Assays, Antitumor / methods. Fatal Outcome. Humans. Immunohistochemistry. Interferon-beta / administration & dosage. Male. Melanoma-Specific Antigens. Neoadjuvant Therapy. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Melanoma.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17965534.001).
  • [ISSN] 1345-4676
  • [Journal-full-title] Journal of Nippon Medical School = Nippon Ika Daigaku zasshi
  • [ISO-abbreviation] J Nippon Med Sch
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Melanoma-Specific Antigens; 0 / Neoplasm Proteins; 77238-31-4 / Interferon-beta; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  •  go-up   go-down


2. Lindner LH, Eichhorn ME, Eibl H, Teichert N, Schmitt-Sody M, Issels RD, Dellian M: Novel temperature-sensitive liposomes with prolonged circulation time. Clin Cancer Res; 2004 Mar 15;10(6):2168-78
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Hyperthermia increases the efficiency of various chemotherapeutic drugs and is administered as an adjunct to chemotherapy for the treatment of cancer patients.
  • The temperature-dependent effect can be strongly increased by the use of temperature-sensitive liposomes in combination with regional hyperthermia, which specifically releases the entrapped drug in the heated tumor tissue.
  • DPPGOG facilitates temperature-triggered drug release from these liposomes (diameter, 175 nm) and leads to a substantially prolonged plasma half-life for the encapsulated drug with t(1/2) = 9.6 h in hamsters and t(1/2) = 5.0 h in rats.
  • Quantitative fluorescence microscopy of amelanotic melanoma grown in the transparent dorsal skin fold chamber of hamsters demonstrated a favorable drug accumulation in heated tissue after i.v. application of these liposomes (42 degrees C for 1 h).
  • The mean area under the curve for tissue drug concentration was increased by more than sixfold by application of the new liposomes compared with nonliposomal drug delivery.
  • In summary, we present a new DPPGOG-based liposomal formulation enabling long circulation time combined with fast and efficient drug release under mild hyperthermia.
  • [MeSH-minor] 1,2-Dipalmitoylphosphatidylcholine. Animals. Capsules. Cricetinae. Drug Carriers. Half-Life. Molecular Conformation. Phosphatidylcholines

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15041738.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Capsules; 0 / Drug Carriers; 0 / Liposomes; 0 / Phosphatidylcholines; 114928-03-9 / di-(8-n-butylstearoyl)phosphatidylcholine; 2644-64-6 / 1,2-Dipalmitoylphosphatidylcholine
  •  go-up   go-down


3. Camerin M, Magaraggia M, Soncin M, Jori G, Moreno M, Chambrier I, Cook MJ, Russell DA: The in vivo efficacy of phthalocyanine-nanoparticle conjugates for the photodynamic therapy of amelanotic melanoma. Eur J Cancer; 2010 Jul;46(10):1910-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The in vivo efficacy of phthalocyanine-nanoparticle conjugates for the photodynamic therapy of amelanotic melanoma.
  • The efficiency of a Zn(II)-phthalocyanine disulphide (C11Pc), a compound with both phthalocyanine units bearing seven hexyl chains and a sulphur terminated C11 chain, as a photodynamic therapy (PDT) agent was investigated in C57 mice bearing a sub-cutaneously transplanted amelanotic melanoma.
  • Biodistribution studies at selected post-injection times showed that the nanoparticle-associated C11Pc was recovered in significantly larger amounts from all the examined tissues and the serum and yielded a greater selectivity of tumour targeting: thus, the ratio between the amount of phthalocyanine recovered from the amelanotic melanoma and the skin (peritumoural tissue) increased from 2.3 to 5.5 from the free to the gold nanoparticle-bound C11Pc at 24 h after injection.
  • PDT studies with the C11Pc-loaded amelanotic melanoma showed a markedly more significant response of the tumour in the mice that had received the nanoparticle-bound photosensitiser; the PDT effect was especially extensive if the irradiation was performed at 3h after C11Pc injection when large phthalocyanine amounts were still present in the serum.
  • [MeSH-major] Indoles / therapeutic use. Melanoma, Amelanotic / drug therapy. Metal Nanoparticles / therapeutic use. Organometallic Compounds / therapeutic use. Photochemotherapy / methods. Photosensitizing Agents / therapeutic use. Skin Neoplasms / drug therapy
  • [MeSH-minor] Animals. Female. Mice. Mice, Inbred C57BL. Neoplasm Transplantation

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20356732.001).
  • [ISSN] 1879-0852
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Grant] United Kingdom / Cancer Research UK / / C22031/A7097
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Indoles; 0 / Organometallic Compounds; 0 / Photosensitizing Agents; 14320-04-8 / Zn(II)-phthalocyanine
  •  go-up   go-down


Advertisement
4. Jain V, Dabir S, Shome D, Dadu T, Natarajan S: Aspergillus iris granuloma: a case report with review of literature. Surv Ophthalmol; 2009 Mar-Apr;54(2):286-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Differential diagnoses of a fungal granuloma, a medulloepithelioma, and an amelanotic melanoma were considered.
  • Absence of a significant systemic history compounded the diagnostic dilemma in our patient.
  • Definitive differentiation of this rare entity from a foreign body, amelanotic melanoma, and other inflammatory conditions such as sarcoidosis and tuberculosis, may be possible only on microbiological and histo-pathological evaluation.
  • [MeSH-minor] Adult. Antifungal Agents / therapeutic use. Aqueous Humor / microbiology. Atropine / therapeutic use. Aza Compounds / therapeutic use. DNA, Fungal / analysis. Drug Therapy, Combination. Fluoroquinolones. Genome, Fungal / genetics. Humans. Male. Natamycin / therapeutic use. Polymerase Chain Reaction. Quinolines / therapeutic use

  • MedlinePlus Health Information. consumer health - Aspergillosis.
  • Hazardous Substances Data Bank. ATROPINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19298905.001).
  • [ISSN] 0039-6257
  • [Journal-full-title] Survey of ophthalmology
  • [ISO-abbreviation] Surv Ophthalmol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antifungal Agents; 0 / Aza Compounds; 0 / DNA, Fungal; 0 / Fluoroquinolones; 0 / Quinolines; 7C0697DR9I / Atropine; 8O0C852CPO / Natamycin; U188XYD42P / moxifloxacin
  • [Number-of-references] 18
  •  go-up   go-down


5. Stroh C, Manger T: [Primary amelanotic anorectal melanoma--a case report]. Zentralbl Chir; 2007 Dec;132(6):560-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary amelanotic anorectal melanoma--a case report].
  • [Transliterated title] Das primäre amelanotische Melanom des Rektums - Ein Fallbericht.
  • BACKGROUND: The amelanotic melanoma of the rectal mucosa is very rare with an unfavourable prognosis.
  • Therefore transrectal ultrasound is of major importance in the preoperative staging and postoperative follow-up especially in diagnosis of local recurrence by using the ultrasound-guided, transrectal aspiration.
  • METHODS: In literature 5 cases of amelanotic malignant melanoma were reported.
  • The overall survival time is 10 months after diagnosis.
  • RESULTS: We report about a 55-year-old female patient with an amelanotic melanoma of rectal mucosa.
  • The patient died 36 months after diagnosis.
  • CONCLUSION: The prognosis of primary malignant anorectal melanoma is poor, irrespective of surgical treatment.
  • Wide local resection is the first choice for primary anorectal melanoma.
  • Chemotherapy, radiotherapy and immunotherapy should be considered in the treatment of anorectal melanoma to influence the overall survival.
  • [MeSH-major] Melanoma, Amelanotic / surgery. Rectal Neoplasms / surgery
  • [MeSH-minor] Chemotherapy, Adjuvant. Disease Progression. Endosonography. Fatal Outcome. Female. Follow-Up Studies. Humans. Intestinal Mucosa / pathology. Intestinal Mucosa / surgery. Intestinal Mucosa / ultrasonography. Lymph Node Excision. Middle Aged. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / surgery. Neoplasm Recurrence, Local / ultrasonography. Neoplasm Staging. Palliative Care. Proctoscopy. Radiotherapy, Adjuvant. Reoperation

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18098086.001).
  • [ISSN] 0044-409X
  • [Journal-full-title] Zentralblatt für Chirurgie
  • [ISO-abbreviation] Zentralbl Chir
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


6. Liu X, Pham TQ, Berghofer P, Chapman J, Greguric I, Mitchell P, Mattner F, Loc'h C, Katsifis A: Synthesis and evaluation of novel radioiodinated nicotinamides for malignant melanoma. Nucl Med Biol; 2008 Oct;35(7):769-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synthesis and evaluation of novel radioiodinated nicotinamides for malignant melanoma.
  • INTRODUCTION: A series of iodonicotinamides based on the melanin-binding iodobenzamide compound N-2-diethylaminoethyl-4-iodobenzamide was prepared and evaluated for the potential imaging and staging of disseminated metastatic melanoma.
  • METHODS: [(123)I]Iodonicotinamides were prepared by iododestannylation reactions using no-carrier-added iodine-123 and evaluated in vivo by biodistribution and competition studies and by single photon emission computed tomography (SPECT) imaging in black and albino nude mice bearing B16F0 murine melanotic and A375 human amelanotic melanoma tumours, respectively.
  • Clearance from the animals by urinary excretion was more rapid for N-alkyl-nicotinamides than for piperazinyl derivatives.
  • SPECT imaging of [(123)I]1 in black mice bearing the B16F0 melanoma indicated that the radioactivity was predominately located in the tumour and eyes.
  • No specific localisation was observed in nude mice bearing A375 amelanotic tumours.
  • CONCLUSION: These findings suggest that [(123)I]1, which displays high tumour uptake with rapid clearance from the body, could be a promising imaging agent for the detection of melanotic tumours.
  • [MeSH-major] Iodine Radioisotopes. Melanoma, Experimental / radionuclide imaging. Niacinamide / metabolism. Radiopharmaceuticals / chemical synthesis
  • [MeSH-minor] Animals. Female. Mice. Mice, Inbred BALB C. Mice, Inbred C57BL. Solubility. Tissue Distribution. Tomography, Emission-Computed, Single-Photon

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. NICOTINAMIDE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18848662.001).
  • [ISSN] 0969-8051
  • [Journal-full-title] Nuclear medicine and biology
  • [ISO-abbreviation] Nucl. Med. Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Iodine Radioisotopes; 0 / Radiopharmaceuticals; 25X51I8RD4 / Niacinamide
  •  go-up   go-down


7. Smith SH, Goldschmidt MH, McManus PM: A comparative review of melanocytic neoplasms. Vet Pathol; 2002 Nov;39(6):651-78
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Melanoma is a devastating disease frequently encountered within both veterinary and human medicine.
  • Molecular changes linked with neoplastic transformation of melanocytes include mutations in genes that encode proteins intrinsic to the regulatory pathways of two tumor suppressor proteins (retinoblastoma protein and p53), proto-oncogene mutation to oncogenes, altered expression of epithelial cadherin and CD44 adhesion molecules, and upregulation of angiogenic factors and other growth factors.
  • Histologic evaluation of the primary mass is the most common means of diagnosis, with cytology used more frequently to document metastasis.
  • Melanoma's highly variable histologic and cytologic patterns can make diagnosis by either method problematic.
  • The site of the tumor, the thickness of the primary tumor or depth of invasion, and the number of mitotic figures per high-power field or per millimeter are used histologically to predict biologic behavior, whereas site and degree of pleomorphism are typically used for cytologic preparations.
  • Diagnosis of amelanotic melanoma can be aided by ancillary diagnostic techniques.
  • Mouse monoclonal antibody IBF9 specifically recognizes canine melanoma antigen and also has good sensitivity.
  • Serologic markers, including cytokines, cell adhesion molecules, and melanoma-inhibitory activity, are being investigated as potential sentinels of melanoma.
  • Currently, there is no single diagnostic technique capable of differentiating benign from malignant melanocytic neoplasms or predicting survival time.
  • [MeSH-major] Cat Diseases / pathology. Dog Diseases / pathology. Horse Diseases / pathology. Melanoma / veterinary. Skin Neoplasms / veterinary
  • [MeSH-minor] Animals. Cats. Dogs. Horses. Humans. Immunohistochemistry / veterinary. Microscopy, Electron


8. Ludwig T, Fakih S, Bertram H, Krebs B, Oberleithner H: New imidazole-coordinated chemotherapeutics with low epithelial toxicity. Cell Biochem Biophys; 2006;45(1):31-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The new imidazole-coordinated chemotherapeutics with low epithelial toxicity (NICE) presented in this article feature innovative drugs that combine epithelial toxicity comparable with that of carboplatin with novel carrier ligands optimized for DNA interaction.
  • Effects of substituents on pharmacological properties of NICE were systematically investigated by introducing sterically demanding groups as well as electron-donating and electron-withdrawing groups.
  • The chlorine substituted NICE had no effect on epithelial integrity but markedly cytotoxic activity against amelanotic melanoma cells.
  • Together, side effect targeted screening for new anticancer drugs with the electrical resistance breakdown assay offers an interesting approach for identifying and investigating new compounds.
  • [MeSH-major] Antineoplastic Agents / toxicity. Carboplatin / toxicity. Epithelial Cells / metabolism. Imidazoles / therapeutic use. Organoplatinum Compounds / toxicity
  • [MeSH-minor] Animals. Caspase 3. Caspases / metabolism. Cell Culture Techniques. Cell Line. Cell Line, Tumor. Cell Membrane / drug effects. Cell Membrane / physiology. Cell Polarity. Cells, Cultured. Clone Cells. Dogs. Electric Impedance. Intracellular Membranes / drug effects. Intracellular Membranes / physiology. Ligands. Molecular Conformation. Organic Cation Transport Proteins / metabolism

  • Hazardous Substances Data Bank. CARBOPLATIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16679562.001).
  • [ISSN] 1085-9195
  • [Journal-full-title] Cell biochemistry and biophysics
  • [ISO-abbreviation] Cell Biochem. Biophys.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Imidazoles; 0 / Ligands; 0 / Organic Cation Transport Proteins; 0 / Organoplatinum Compounds; BG3F62OND5 / Carboplatin; EC 3.4.22.- / Caspase 3; EC 3.4.22.- / Caspases
  •  go-up   go-down


9. Tundis R, Deguin B, Loizzo MR, Bonesi M, Statti GA, Tillequin F, Menichini F: Potential antitumor agents: flavones and their derivatives from Linaria reflexa Desf. Bioorg Med Chem Lett; 2005 Nov 1;15(21):4757-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Potential antitumor agents: flavones and their derivatives from Linaria reflexa Desf.
  • The antiproliferative activity of several flavonoids isolated from Linaria reflexa Desf. (Scrophulariaceae) was evaluated in vitro by the SRB assay against the large cell lung carcinoma cell line COR-L23, hepatocellular carcinoma cell line HepG-2, renal adenocarcinoma cell line ACHN, amelanotic melanoma cell line C32, colorectal adenocarcinoma cell line Caco-2, and normal human fetal lung MRC5.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / pharmacology. Flavones / pharmacology. Linaria / chemistry
  • [MeSH-minor] Acetylation. Cell Line, Tumor. Cell Proliferation / drug effects. Chromones / chemistry. Chromones / pharmacology. Drug Screening Assays, Antitumor. Humans. Hydrolysis. Inhibitory Concentration 50. Structure-Activity Relationship

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16125932.001).
  • [ISSN] 0960-894X
  • [Journal-full-title] Bioorganic & medicinal chemistry letters
  • [ISO-abbreviation] Bioorg. Med. Chem. Lett.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Chromones; 0 / Flavones; 28978-02-1 / pectolinarin
  •  go-up   go-down


10. Ludwig T, Fakih S, Krebs B, Oberleithner H: Platinum complex cytotoxicity tested by the electrical resistance breakdown assay. Cell Physiol Biochem; 2004;14(4-6):425-30
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The electrical resistance breakdown assay provides a novel approach for the quantification of cytotoxic activity of platinum based anticancer drugs.
  • We measured changes in transepithelial electrical resistance (TEER) of a tight epithelial MDCK-C7 monolayer in response to highly invasive amelanotic melanoma cells (A7-clone) in combination with different platinum complexes (cis-, oxali- and carboplatin).
  • When human melanoma cells were seeded on top of an electrically tight MDCK-C7 monolayer, electrical leakage occurred within 48 h of co-culture.
  • [MeSH-major] Antineoplastic Agents / toxicity. Drug Evaluation, Preclinical / methods. Platinum Compounds / toxicity
  • [MeSH-minor] Animals. Biological Assay / instrumentation. Cell Line, Tumor. Dogs. Electric Impedance. Epithelial Cells / drug effects. Epithelial Cells / physiology. Humans. Melanoma, Amelanotic / chemistry. Melanoma, Amelanotic / metabolism

  • Hazardous Substances Data Bank. PLATINUM COMPOUNDS .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2004 S. Karger AG, Basel
  • (PMID = 15319546.001).
  • [ISSN] 1015-8987
  • [Journal-full-title] Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology
  • [ISO-abbreviation] Cell. Physiol. Biochem.
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Platinum Compounds
  •  go-up   go-down


11. Chen M, Pych E, Corpron C, Harmon CM: Regulation of CD36 expression in human melanoma cells. Adv Exp Med Biol; 2002;507:337-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Regulation of CD36 expression in human melanoma cells.
  • The human amelanotic melanoma cell line, C32, is known to express CD36 and has been as a model for studying TSP binding.
  • [MeSH-major] Antigens, CD36 / genetics. Gene Expression Regulation, Neoplastic / immunology. Melanoma / genetics
  • [MeSH-minor] Anti-Inflammatory Agents, Non-Steroidal / pharmacology. Antigens, CD / genetics. Humans. Ibuprofen / pharmacology. Insulin / pharmacology. RNA, Messenger / genetics. Tetradecanoylphorbol Acetate / pharmacology. Transcription, Genetic / drug effects. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Melanoma.
  • Hazardous Substances Data Bank. IBUPROFEN .
  • Hazardous Substances Data Bank. 12-O-TETRADECANOYLPHORBOL-13-ACETATE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12664607.001).
  • [ISSN] 0065-2598
  • [Journal-full-title] Advances in experimental medicine and biology
  • [ISO-abbreviation] Adv. Exp. Med. Biol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Antigens, CD; 0 / Antigens, CD36; 0 / Insulin; 0 / RNA, Messenger; NI40JAQ945 / Tetradecanoylphorbol Acetate; WK2XYI10QM / Ibuprofen
  •  go-up   go-down


12. El Abdaimi K, Papavasiliou V, Goltzman D, Kremer R: Expression and regulation of parathyroid hormone-related peptide in normal and malignant melanocytes. Am J Physiol Cell Physiol; 2000 Oct;279(4):C1230-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression and regulation of parathyroid hormone-related peptide in normal and malignant melanocytes.
  • We examined parathyroid hormone-related peptide (PTHrP) production and regulation in both normal human melanocytes and in a human amelanotic melanoma cell line (A375).
  • Our study, therefore, demonstrates a stepwise increase in PTHrP expression when cells progress from normal to malignant phenotype and suggests that EB-1089 should be further evaluated as a therapeutic agent in human melanoma.
  • [MeSH-major] Calcitriol / analogs & derivatives. Melanocytes / metabolism. Melanoma, Amelanotic / metabolism. Proteins / metabolism. Skin Neoplasms / metabolism
  • [MeSH-minor] Animals. Antineoplastic Agents / administration & dosage. Blotting, Northern. Body Weight / drug effects. Calcium / blood. Cell Division / drug effects. Cell Line. Drug Implants. Female. Fibroblast Growth Factor 2 / pharmacology. Humans. Hypercalcemia / blood. Immunohistochemistry. Insulin / pharmacology. Mice. Mice, SCID. Neoplasm Transplantation. Parathyroid Hormone-Related Protein. RNA, Messenger / biosynthesis

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. 1,25-DIHYDROXYCHOLECALCIFEROL .
  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11003603.001).
  • [ISSN] 0363-6143
  • [Journal-full-title] American journal of physiology. Cell physiology
  • [ISO-abbreviation] Am. J. Physiol., Cell Physiol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Drug Implants; 0 / Insulin; 0 / PTHLH protein, human; 0 / Parathyroid Hormone-Related Protein; 0 / Proteins; 0 / RNA, Messenger; 103107-01-3 / Fibroblast Growth Factor 2; FXC9231JVH / Calcitriol; Q0OZ0D9223 / seocalcitol; SY7Q814VUP / Calcium
  •  go-up   go-down


13. Auer-Grumbach M: Hereditary sensory neuropathy type I. Orphanet J Rare Dis; 2008;3:7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hereditary sensory neuropathy type I.
  • Hereditary sensory neuropathy type I (HSN I) is a slowly progressive neurological disorder characterised by prominent predominantly distal sensory loss, autonomic disturbances, autosomal dominant inheritance, and juvenile or adulthood disease onset.
  • Variable distal muscle weakness and wasting, and chronic skin ulcers are characteristic.
  • Diagnosis is based on the clinical observation and is supported by a family history.
  • Definitive diagnosis is based on the detection of mutations by direct sequencing of the SPTLC1 and RAB7 genes.
  • Correct clinical assessment and genetic confirmation of the diagnosis are important for appropriate genetic counselling and prognosis.
  • Differential diagnosis includes the other hereditary sensory and autonomic neuropathies (HSAN), especially HSAN II, as well as diabetic foot syndrome, alcoholic neuropathy, neuropathies caused by other neurotoxins/drugs, immune mediated neuropathy, amyloidosis, spinal cord diseases, tabes dorsalis, lepra neuropathy, or decaying skin tumours like amelanotic melanoma.
  • The disorder is slowly progressive and does not influence life expectancy but is often severely disabling after a long duration of the disease.

  • The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for hereditary sensory neuropathy .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Cell Biol. 1999 Oct;1(6):376-82 [10559966.001]
  • [Cites] Curr Opin Neurol. 2006 Oct;19(5):474-80 [16969157.001]
  • [Cites] Neurology. 2000 Nov 28;55(10):1552-7 [11094113.001]
  • [Cites] Muscle Nerve. 2000 Oct;23(10):1508-14 [11003785.001]
  • [Cites] Nat Genet. 2001 Mar;27(3):261-2 [11242106.001]
  • [Cites] Nat Genet. 2001 Mar;27(3):309-12 [11242114.001]
  • [Cites] Am J Hum Genet. 2001 Sep;69(3):655-9 [11479835.001]
  • [Cites] Neuromuscul Disord. 2002 Mar;12(3):286-91 [11801401.001]
  • [Cites] J Biol Chem. 2002 Mar 22;277(12):10194-200 [11781309.001]
  • [Cites] Neuromuscul Disord. 2002 Oct;12(7-8):656-8 [12207934.001]
  • [Cites] J Clin Invest. 2002 Nov;110(9):1301-8 [12417569.001]
  • [Cites] Am J Hum Genet. 2003 Mar;72(3):722-7 [12545426.001]
  • [Cites] Arch Neurol. 2003 Mar;60(3):329-34 [12633143.001]
  • [Cites] Biochim Biophys Acta. 2003 Jun 10;1632(1-3):16-30 [12782147.001]
  • [Cites] Am J Hum Genet. 2003 Sep;73(3):632-7 [12870133.001]
  • [Cites] Biochim Biophys Acta. 2004 Mar 2;1688(2):168-75 [14990347.001]
  • [Cites] Neurology. 2004 Mar 23;62(6):1001-2 [15037712.001]
  • [Cites] Curr Opin Neurol. 2004 Oct;17(5):569-77 [15367861.001]
  • [Cites] Ann Neurol. 2004 Oct;56(4):586-90 [15455439.001]
  • [Cites] Arch Neurol. 1974 May;30(5):359-71 [4132408.001]
  • [Cites] Am J Hum Genet. 1995 Oct;57(4):853-8 [7573046.001]
  • [Cites] Nat Genet. 1996 May;13(1):101-4 [8673084.001]
  • [Cites] Am J Hum Genet. 1996 Jul;59(1):258-62 [8659534.001]
  • [Cites] Neurology. 1997 Jan;48(1):23-8 [9008488.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1997 Jun;62(6):570-3 [9219740.001]
  • [Cites] Science. 1998 Jan 23;279(5350):580-5 [9438855.001]
  • [Cites] J Neurol Sci. 2004 Dec 15;227(1):35-8 [15546589.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2005 Jul;76(7):1022-4 [15965219.001]
  • [Cites] Brain. 2005 Dec;128(Pt 12):2797-810 [16311270.001]
  • [Cites] Brain. 2006 Feb;129(Pt 2):411-25 [16364956.001]
  • [Cites] Neurology. 2000 Jan 11;54(1):45-52 [10636124.001]
  • (PMID = 18348718.001).
  • [ISSN] 1750-1172
  • [Journal-full-title] Orphanet journal of rare diseases
  • [ISO-abbreviation] Orphanet J Rare Dis
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Number-of-references] 35
  • [Other-IDs] NLM/ PMC2311280
  •  go-up   go-down


14. Pouckova P, Skvor J, Gotte G, Vottariello F, Slavik JT, Matousek J, Laurents DV, Libonati M, Soucek J: Some biological actions of PEG-conjugated RNase A oligomers. Neoplasma; 2006;53(1):79-85
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Some biological actions of PEG-conjugated RNase A oligomers.
  • Previously we have shown that monomeric RNase A has no significant biological activity, whereas its oligomers (dimer to tetramer) prepared by lyophilizing from 50% acetic acid solutions, show remarkable aspermatogenic and antitumor activities.
  • In this work we show that the chemical conjugation of PEG to the RNase A C-dimer, and to the two RNase A trimers (NC-trimer and C- trimer) decreases the aspermatogenic activity of the oligomers while increasing their inhibitory activity on the growth of the human UB900518 amelanotic melanoma transplanted in athymic nude mice.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Peptide Fragments / pharmacology. Polyethylene Glycols / pharmacology. Ribonuclease, Pancreatic / pharmacology
  • [MeSH-minor] Animals. Antispermatogenic Agents / pharmacology. Cell Line, Tumor. Dimerization. Embryo, Mammalian / drug effects. Humans. Male. Melanoma, Experimental / drug therapy. Mice. Neoplasm Transplantation. Spermatogenesis / drug effects

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16416018.001).
  • [ISSN] 0028-2685
  • [Journal-full-title] Neoplasma
  • [ISO-abbreviation] Neoplasma
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Slovakia
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antispermatogenic Agents; 0 / Peptide Fragments; 30IQX730WE / Polyethylene Glycols; EC 3.1.27.5 / Ribonuclease, Pancreatic
  •  go-up   go-down


15. Schneider G, Seidel R, Uder M, Wagner D, Weinmann HJ, Kramann B: In vivo microscopic evaluation of the microvascular behavior of FITC-labeled macromolecular MR contrast agents in the hamster skinfold chamber. Invest Radiol; 2000 Sep;35(9):564-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In vivo microscopic evaluation of the microvascular behavior of FITC-labeled macromolecular MR contrast agents in the hamster skinfold chamber.
  • After implantation of a dorsal skinfold chamber and 7 days (range, 6-8) after induction of an amelanotic melanoma (A-Mel-3), 14 male hamsters weighing 85 g (range, 70-95 g) received 200 micromol/kg of CM1 by intravenous injection into the jugular vein.
  • [MeSH-major] Contrast Media. Extravasation of Diagnostic and Therapeutic Materials. Fluorescein-5-isothiocyanate. Gadolinium DTPA. Heterocyclic Compounds. Magnetic Resonance Imaging. Melanoma, Amelanotic / diagnosis. Melanoma, Experimental / diagnosis. Microscopy, Fluorescence. Organometallic Compounds. Skin Neoplasms / diagnosis
  • [MeSH-minor] Animals. Capillary Permeability. Cricetinae. Fluorescent Dyes. Gadolinium. Male. Microcirculation. Random Allocation. Time Factors. Video Recording

  • MedlinePlus Health Information. consumer health - MRI Scans.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. GADOLINIUM, ELEMENTAL .
  • Hazardous Substances Data Bank. GADOPENTETATE DIMEGLUMINE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10982002.001).
  • [ISSN] 0020-9996
  • [Journal-full-title] Investigative radiology
  • [ISO-abbreviation] Invest Radiol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Contrast Media; 0 / Fluorescent Dyes; 0 / Heterocyclic Compounds; 0 / Organometallic Compounds; 92923-44-9 / gadolinium 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetate; AU0V1LM3JT / Gadolinium; I223NX31W9 / Fluorescein-5-isothiocyanate; K2I13DR72L / Gadolinium DTPA
  •  go-up   go-down


16. Sinicropi MS, Caruso A, Conforti F, Marrelli M, El Kashef H, Lancelot JC, Rault S, Statti GA, Menichini F: Synthesis, inhibition of NO production and antiproliferative activities of some indole derivatives. J Enzyme Inhib Med Chem; 2009 Oct;24(5):1148-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The synthesis and the biological evaluation of pyrano[3,2-e]indoles and their reaction intermediates are described.
  • The compounds prepared were evaluated for their inhibition of NO production, antioxidant activity and also for their ability to inhibit in vitro the growth of four human tumor cell lines: large lung carcinoma (COR-L23), alveolar basal epithelial carcinoma (A549), amelanotic melanoma (C32) and melanoma (A375).
  • Compound 5a was the most active against melanotic melanoma (IC(50) = 11.8 microM) while the other compounds exhibited weak cytotoxicity with IC(50) values >50 microM on all cell lines.
  • [MeSH-major] Antineoplastic Agents / chemical synthesis. Indoles. Nitric Oxide / antagonists & inhibitors. Pyrans
  • [MeSH-minor] Animals. Cell Line, Tumor. Cell Proliferation / drug effects. Humans. Inhibitory Concentration 50. Mice. Molecular Structure

  • Hazardous Substances Data Bank. NITRIC OXIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19555184.001).
  • [ISSN] 1475-6374
  • [Journal-full-title] Journal of enzyme inhibition and medicinal chemistry
  • [ISO-abbreviation] J Enzyme Inhib Med Chem
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Indoles; 0 / Pyrans; 31C4KY9ESH / Nitric Oxide
  •  go-up   go-down


17. Di Domenico F, Foppoli C, Blarzino C, Perluigi M, Paolini F, Morici S, Coccia R, Cini C, De Marco F: Expression of human papilloma virus type 16 E5 protein in amelanotic melanoma cells regulates endo-cellular pH and restores tyrosinase activity. J Exp Clin Cancer Res; 2009;28:4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of human papilloma virus type 16 E5 protein in amelanotic melanoma cells regulates endo-cellular pH and restores tyrosinase activity.
  • In tyrosinase-positive amelanotic melanomas this rate limiting enzyme is inactive because of acidic endo-melanosomal pH.
  • The E5 oncogene of the Human Papillomavirus Type 16 is a small transmembrane protein with a weak transforming activity and a role during the early steps of viral infections.
  • METHODS: The expression of the HPV16-E5 oncoproteins was induced in two Tyrosinase-positive amelanotic melanomas (the cell lines FRM and M14) by a retroviral expression construct.
  • These effects are associated with an increased activation of tyrosine analogue anti-blastic drugs.
  • In amelanotic melanomas these effects can modulate the cell phenotype and can induce a higher sensitivity to tyrosine related anti-blastic drugs.
  • [MeSH-major] Melanoma, Amelanotic / metabolism. Monophenol Monooxygenase / metabolism. Oncogene Proteins, Viral / metabolism. Skin Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • Cellosaurus - a cell line knowledge resource. culture/stock collections - Cellosaurus - a cell line knowledge resource .
  • Hazardous Substances Data Bank. DOPAMINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Exp Biol. 2000 Jan;203(Pt 1):61-70 [10600674.001]
  • [Cites] Oncogene. 2000 Aug 3;19(33):3727-32 [10949926.001]
  • [Cites] Br J Cancer. 2000 Jul;83(2):184-7 [10901368.001]
  • [Cites] FEBS Lett. 2000 Jul 28;478(1-2):57-60 [10922469.001]
  • [Cites] Exp Cell Res. 2001 Jan 15;262(2):197-208 [11139343.001]
  • [Cites] Oncogene. 2000 Dec 7;19(52):6023-32 [11146554.001]
  • [Cites] Exp Cell Res. 2001 Aug 1;268(1):26-35 [11461115.001]
  • [Cites] J Gen Virol. 2001 Oct;82(Pt 10):2353-62 [11562529.001]
  • [Cites] Oncogene. 2001 Nov 26;20(54):7866-73 [11753669.001]
  • [Cites] Oncogene. 2002 Jan 10;21(2):248-59 [11803468.001]
  • [Cites] Nat Rev Cancer. 2002 May;2(5):342-50 [12044010.001]
  • [Cites] Oncol Res. 2002;13(1):3-8 [12201672.001]
  • [Cites] Biochem Pharmacol. 2002 Nov 15;64(10):1503-12 [12417263.001]
  • [Cites] Cancer Res. 2003 Jan 15;63(2):441-8 [12543800.001]
  • [Cites] Virology. 2003 May 25;310(1):100-8 [12788634.001]
  • [Cites] J Biol Chem. 2004 Feb 27;279(9):7971-81 [14634018.001]
  • [Cites] Cell. 1983 May;33(1):153-9 [6678608.001]
  • [Cites] J Immunol Methods. 1986 Nov 20;94(1-2):57-63 [3782817.001]
  • [Cites] Proc Natl Acad Sci U S A. 1988 Nov;85(21):7972-6 [2973058.001]
  • [Cites] J Virol. 1989 Oct;63(10):4417-21 [2476573.001]
  • [Cites] J Virol. 1990 Jul;64(7):3226-33 [2161939.001]
  • [Cites] Pigment Cell Res. 1990 Mar-Apr;3(2):49-54 [2117268.001]
  • [Cites] Anal Biochem. 1991 Feb 1;192(2):316-21 [1827963.001]
  • [Cites] J Biol Regul Homeost Agents. 1991 Apr-Jun;5(2):65-70 [1716817.001]
  • [Cites] J Virol. 1991 Dec;65(12):7078-83 [1658398.001]
  • [Cites] Biochemistry. 1993 Apr 20;32(15):3902-6 [8385991.001]
  • [Cites] J Invest Dermatol. 1993 Jun;100(6):806-11 [8496620.001]
  • [Cites] J Virol. 1993 Aug;67(8):4521-32 [8392596.001]
  • [Cites] J Virol. 1993 Oct;67(10):6170-8 [7690419.001]
  • [Cites] Virology. 1994 Aug 15;203(1):73-80 [8030286.001]
  • [Cites] J Virol. 1995 May;69(5):3185-92 [7707548.001]
  • [Cites] J Gen Virol. 1995 May;76 ( Pt 5):1239-45 [7730808.001]
  • [Cites] J Virol. 1995 Dec;69(12):8051-6 [7494320.001]
  • [Cites] Biochim Biophys Acta. 1996 Oct 9;1288(2):F55-78 [8876633.001]
  • [Cites] Cancer Res. 1998 Apr 1;58(7):1521-3 [9537258.001]
  • [Cites] Exp Cell Res. 1998 May 25;241(1):76-83 [9633515.001]
  • [Cites] Int J Cancer. 2005 Jan 10;113(2):276-83 [15386416.001]
  • [Cites] J Virol. 2004 Dec;78(24):13613-26 [15564472.001]
  • [Cites] Arch Virol. 2005 Feb;150(2):231-46 [15503216.001]
  • [Cites] Virology. 2005 Feb 5;332(1):102-13 [15661144.001]
  • [Cites] Int J Biochem Cell Biol. 2005 Apr;37(4):852-63 [15694844.001]
  • [Cites] Virology. 2005 Jun 20;337(1):76-84 [15914222.001]
  • [Cites] Neoplasia. 2006 Jul;8(7):543-50 [16867216.001]
  • [Cites] Oncogene. 2008 Feb 14;27(8):1071-8 [17704805.001]
  • [Cites] Virol J. 2008;5:30 [18302753.001]
  • [Cites] Oncogene. 2008 Apr 17;27(18):2532-41 [17982485.001]
  • [Cites] Virology. 2000 Jul 5;272(2):315-25 [10873774.001]
  • (PMID = 19133143.001).
  • [ISSN] 1756-9966
  • [Journal-full-title] Journal of experimental & clinical cancer research : CR
  • [ISO-abbreviation] J. Exp. Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Melanins; 0 / Oncogene Proteins, Viral; 0 / Proton Pump Inhibitors; 0 / RNA, Messenger; 0 / oncogene protein E5, Human papillomavirus type 16; 37491-68-2 / 3,4-dihydroxybenzylamine; 5072-26-4 / Buthionine Sulfoximine; EC 1.14.18.1 / Monophenol Monooxygenase; VTD58H1Z2X / Dopamine
  • [Other-IDs] NLM/ PMC2654431
  •  go-up   go-down


18. Mishima Y, Kondoh H: Dual control of melanogenesis and melanoma growth: overview molecular to clinical level and the reverse. Pigment Cell Res; 2000;13 Suppl 8:10-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dual control of melanogenesis and melanoma growth: overview molecular to clinical level and the reverse.
  • Utilizing increased melanin pigmentation and accentuated melanogenesis seen in malignant melanoma, we newly developed melanoma-selective boron neutron capture therapy (BNCT) after designing and synthesizing the 10B-DOPA analogue, 10B-p-boronophenylalanine (10B-BPA).
  • After multi-disciplined and extensive basic and pre-clinical investigations, we successfully treated 18 cases of human melanoma.
  • Recently, we found that accentuated synthesis of melanin monomers, richest within coated vesicles (CV) in melanoma cells, plays a critical role in attracting 10B-BPA through chemical complex formation of monomers and 10B-BPA.
  • Our discovery, that single molecule 10B-BPA possesses the dual nature of eradication of melanoma with BNCT and suppression of melanin hyperpigmentation, resulted from pursuing bilateral feedback at each stage from pure science to clinical application and vice versa.
  • This also has its roots in clinical hurdles faced in treating amelanotic melanomas by 10B-BPA BNCT.
  • The transfer of tyrosinase and melanin monomer synthesis-related genes into target cancer cells has produced more effective BNCT and may lead to gBNCT for non-melanoma cancers.

  • MedlinePlus Health Information. consumer health - Melanoma.
  • Hazardous Substances Data Bank. BORON COMPOUNDS .
  • Hazardous Substances Data Bank. (L)-Phenylalanine .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11041353.001).
  • [ISSN] 0893-5785
  • [Journal-full-title] Pigment cell research
  • [ISO-abbreviation] Pigment Cell Res.
  • [Language] ENG
  • [Publication-type] Lectures
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Boron Compounds; 0 / Indolequinones; 0 / Indoles; 0 / Melanins; 0 / Quinones; 3571-34-4 / dopachrome; 47E5O17Y3R / Phenylalanine; UID84303EL / 4-boronophenylalanine
  •  go-up   go-down


19. Nihal M, Ahmad N, Mukhtar H, Wood GS: Anti-proliferative and proapoptotic effects of (-)-epigallocatechin-3-gallate on human melanoma: possible implications for the chemoprevention of melanoma. Int J Cancer; 2005 Apr 20;114(4):513-21
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anti-proliferative and proapoptotic effects of (-)-epigallocatechin-3-gallate on human melanoma: possible implications for the chemoprevention of melanoma.
  • Melanoma accounts for only about 4% of all skin cancer cases but most of skin cancer-related deaths.
  • Standard systemic therapies such as interferon (IFN) have not been adequately effective in the management of melanoma.
  • Chemoprevention by naturally occurring agents present in food and beverages has shown benefits in certain cancers including nonmelanoma skin cancers.
  • Here, employing 2 human melanoma cell lines (A-375 amelanotic malignant melanoma and Hs-294T metastatic melanoma) and normal human epidermal melanocytes (NHEM), we studied the antiproliferative effects of epigallocatechin-3-gallate (EGCG), the major polyphenolic antioxidant present in green tea.
  • EGCG treatment was found to result in a dose-dependent decrease in the viability and growth of both melanoma cell lines.
  • EGCG treatment of the melanoma cell lines resulted in decreased cell proliferation (as assessed by Ki-67 and PCNA protein levels) and induction of apoptosis (as assessed cleavage of PARP, TUNEL assay and JC-1 assay).
  • EGCG also significantly inhibited the colony formation ability of the melanoma cells studied.
  • EGCG treatment of melanoma cells resulted in a downmodulation of anti-apoptotic protein Bcl2, upregulation of proapoptotic Bax and activation of caspases -3, -7 and -9.
  • Our data suggest that EGCG causes significant induction of cell cycle arrest and apoptosis of melanoma cells that is mediated via modulations in the cki-cyclin-cdk network and Bcl2 family proteins.
  • Thus, EGCG, alone or in conjunction with current therapies, could be useful for the management of melanoma.
  • [MeSH-major] Anticarcinogenic Agents / pharmacology. Apoptosis. Catechin / analogs & derivatives. Catechin / pharmacology. Melanoma / drug therapy. Melanoma / prevention & control
  • [MeSH-minor] Agar / chemistry. Caspase 3. Caspase 7. Caspase 9. Caspases / metabolism. Cell Cycle. Cell Cycle Proteins / metabolism. Cell Line, Tumor. Cell Proliferation. Cell Separation. Cell Survival. Cyclin-Dependent Kinase Inhibitor p16 / metabolism. Cyclin-Dependent Kinase Inhibitor p21. Dose-Response Relationship, Drug. Down-Regulation. Flow Cytometry. Humans. Immunoblotting. Immunohistochemistry. In Situ Nick-End Labeling. Ki-67 Antigen / biosynthesis. Melanocytes / metabolism. Membrane Potentials. Mitochondria / metabolism. Poly(ADP-ribose) Polymerases / metabolism. Proto-Oncogene Proteins c-bcl-2 / metabolism. Time Factors. bcl-2-Associated X Protein

  • MedlinePlus Health Information. consumer health - Melanoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. AGAR-AGAR .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15609335.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Grant] United States / NIAMS NIH HHS / AR / AR002136-06
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anticarcinogenic Agents; 0 / BAX protein, human; 0 / CDKN1A protein, human; 0 / Cell Cycle Proteins; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / Ki-67 Antigen; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / bcl-2-Associated X Protein; 8R1V1STN48 / Catechin; 9002-18-0 / Agar; BQM438CTEL / epigallocatechin gallate; EC 2.4.2.30 / Poly(ADP-ribose) Polymerases; EC 3.4.22.- / CASP3 protein, human; EC 3.4.22.- / CASP7 protein, human; EC 3.4.22.- / CASP9 protein, human; EC 3.4.22.- / Caspase 3; EC 3.4.22.- / Caspase 7; EC 3.4.22.- / Caspase 9; EC 3.4.22.- / Caspases
  •  go-up   go-down


20. Pham TQ, Berghofer P, Liu X, Greguric I, Dikic B, Ballantyne P, Mattner F, Nguyen V, Loc'h C, Katsifis A: Preparation and biologic evaluation of a novel radioiodinated benzylpiperazine, 123I-MEL037, for malignant melanoma. J Nucl Med; 2007 Aug;48(8):1348-56
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preparation and biologic evaluation of a novel radioiodinated benzylpiperazine, 123I-MEL037, for malignant melanoma.
  • Radiopharmaceuticals that can target the random metastatic dissemination of melanoma tumors may present opportunities for imaging and staging the disease as well as potential radiotherapeutic applications.
  • A novel molecule, 2-(2-(4-(4-(123)I-iodobenzyl)piperazin-1-yl)-2-oxoethyl)isoindoline-1,3-dione (MEL037), was synthesized, labeled with 123I, and evaluated for application in melanoma tumor scintigraphy and radiotherapy.
  • METHODS: The tumor imaging potential of 123I-MEL037 was studied in vivo in C57BL/6J female mice bearing the B16F0 murine melanoma tumor and in BALB/c nude mice bearing the A375 human amelanotic melanoma tumor by biodistribution, competition studies, and SPECT.
  • RESULTS: 123I-MEL037 exhibited high and rapid uptake in the B16F0 melanoma tumor at 1 h (13 %ID/g [percentage injected dose per gram]), increasing with time to reach 25 %ID/g at 6 h.
  • At 24 h after injection of mice bearing the B16 melanoma, SPECT indicated that the radioactivity was located predominately in the tumor followed by the eyes, whereas no specific localization of the radioactivity was noted in mice bearing the A375 human amelanotic tumor.
  • In competition experiments, uptake of 123I-MEL037 in brain, lung, heart, and kidney--organs known to contain sigma-receptors--was not significantly different in haloperidol-treated animals compared with control animals.
  • CONCLUSION: These findings suggested that 123I-MEL037, which displays a rapid and very high tumor uptake, appeared to be a promising imaging agent for detection of most melanoma tumors with the potential for development as a therapeutic agent in melanoma tumor proliferation.
  • [MeSH-major] Iodine Radioisotopes. Melanoma / radionuclide imaging. Radiopharmaceuticals
  • [MeSH-minor] Animals. Female. Haloperidol / pharmacology. Mice. Mice, Inbred BALB C. Mice, Inbred C57BL. Piperazines / metabolism. Tissue Distribution. Tomography, Emission-Computed, Single-Photon

  • MedlinePlus Health Information. consumer health - Melanoma.
  • Hazardous Substances Data Bank. HALOPERIDOL .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17631542.001).
  • [ISSN] 0161-5505
  • [Journal-full-title] Journal of nuclear medicine : official publication, Society of Nuclear Medicine
  • [ISO-abbreviation] J. Nucl. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Iodine Radioisotopes; 0 / Piperazines; 0 / Radiopharmaceuticals; J6292F8L3D / Haloperidol
  •  go-up   go-down


21. De Marco F, Perluigi M, Marcante ML, Coccia R, Foppoli C, Blarzino C, Rosei MA: Cytotoxicity of dopamine-derived tetrahydroisoquinolines on melanoma cells. Biochem Pharmacol; 2002 Nov 15;64(10):1503-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytotoxicity of dopamine-derived tetrahydroisoquinolines on melanoma cells.
  • No data are at present available on TIQ levels in skin, although in vitro biochemical evidences indicate that they may undergo auto-oxidation with production of reactive oxygen species or may be enzymatically converted into melanin pigments.
  • The effect of two catechol-bearing TIQs, salsolinol (SAL) and tetrahydropapaveroline (THP), on the viability of melanotic or amelanotic melanoma cell lines was investigated.
  • The results support the evidence that TIQs were toxic toward melanoma cells, leading to their death by necrosis.
  • [MeSH-major] Dopamine / chemistry. Isoquinolines / pharmacology. Melanoma / pathology. Tetrahydroisoquinolines
  • [MeSH-minor] Antioxidants / pharmacology. Cell Survival / drug effects. Drug Interactions. Humans. Ketoglutarate Dehydrogenase Complex / metabolism. Monophenol Monooxygenase / metabolism. Neurotoxins / pharmacology. RNA, Messenger / biosynthesis. RNA, Messenger / drug effects. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Melanoma.
  • Cellosaurus - a cell line knowledge resource. culture/stock collections - Cellosaurus - a cell line knowledge resource .
  • Cellosaurus - a cell line knowledge resource. culture/stock collections - Cellosaurus - a cell line knowledge resource .
  • Hazardous Substances Data Bank. DOPAMINE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12417263.001).
  • [ISSN] 0006-2952
  • [Journal-full-title] Biochemical pharmacology
  • [ISO-abbreviation] Biochem. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antioxidants; 0 / Isoquinolines; 0 / Neurotoxins; 0 / RNA, Messenger; 0 / Tetrahydroisoquinolines; 91-21-4 / 1,2,3,4-tetrahydroisoquinoline; EC 1.14.18.1 / Monophenol Monooxygenase; EC 1.2.4.2 / Ketoglutarate Dehydrogenase Complex; VTD58H1Z2X / Dopamine
  •  go-up   go-down


22. Loizzo MR, Tundis R, Menichini F, Saab AM, Statti GA, Menichini F: Cytotoxic activity of essential oils from labiatae and lauraceae families against in vitro human tumor models. Anticancer Res; 2007 Sep-Oct;27(5A):3293-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The cytotoxic activity was evaluated in amelanotic melanoma C32, renal cell adenocarcinoma ACHN, hormone-dependent prostate carcinoma LNCaP, and MCF-7 breast cancer cell lines by the sulforhodamine B (SRB) assay.
  • The activity of S. perfoliata oil on both cell lines (IC50 of 100.90 mg/ml for C32 and 98.58 microg/ml for ACHN, respectively) was also interesting.
  • CONCLUSION: This study suggests for the first time the ability of S. perfoliata, S. thymbra, S. officinalis, L. nobilis and P. palestina essential oils and some identified terpenes to inhibit human tumor cell growth.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / pharmacology. Lamiaceae / chemistry. Lauraceae / chemistry. Oils, Volatile / pharmacology. Plant Extracts / pharmacology
  • [MeSH-minor] Cell Line, Tumor. Drug Screening Assays, Antitumor. Gas Chromatography-Mass Spectrometry. Humans

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17970073.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Oils, Volatile; 0 / Plant Extracts
  •  go-up   go-down


23. Bjørnaes I, Halsør EF, Skretting A, Rofstad EK: Measurement of the extracellular volume of human melanoma xenografts by contrast enhanced magnetic resonance imaging. Magn Reson Imaging; 2000 Jan;18(1):41-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Measurement of the extracellular volume of human melanoma xenografts by contrast enhanced magnetic resonance imaging.
  • The magnitude of the extracellular volume fraction (ECV) of tumors is of importance for the transport of macromolecular therapeutic agents from the vessel wall to the tumor cells.
  • Tumors of two human amelanotic melanoma xenograft lines (A-07 and R-18) grown intradermally in Balb/c nu/nu mice were used as model system, and muscle tissue was used as control.
  • [MeSH-major] Contrast Media / administration & dosage. Extracellular Space. Gadolinium DTPA. Magnetic Resonance Imaging / methods. Melanoma, Amelanotic / pathology
  • [MeSH-minor] Animals. Artifacts. Humans. Injections, Intravenous. Mice. Mice, Inbred BALB C. Neoplasm Transplantation. Transplantation, Heterologous. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - MRI Scans.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. GADOPENTETATE DIMEGLUMINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10642101.001).
  • [ISSN] 0730-725X
  • [Journal-full-title] Magnetic resonance imaging
  • [ISO-abbreviation] Magn Reson Imaging
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Contrast Media; K2I13DR72L / Gadolinium DTPA
  •  go-up   go-down


24. Labarre P, Papon J, Moreau MF, Moins N, Bayle M, Veyre A, Madelmont JC: Melanin affinity of N-(2-diethylaminoethyl)-4-iodobenzamide, an effective melanoma imaging agent. Melanoma Res; 2002 Apr;12(2):115-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Melanin affinity of N-(2-diethylaminoethyl)-4-iodobenzamide, an effective melanoma imaging agent.
  • The cellular uptake and incorporation in macromolecules of iodine-125 labelled N-(2-diethylaminoethyl)-4-iodobenzamide ([125I]BZA), a melanoma imaging agent, was studied using human melanoma cells M3Dau (amelanotic) and M4Beu (melanotic).
  • The results showed that uptake was high only for M4Beu, whereas the incorporation in trichloroacetic acid-precipitable proteins was very low for both model cell lines, with no correlation with melanin content.
  • The affinity of BZA for melanin might explain the good results obtained in a phase II clinical trial for the diagnosis of malignant melanoma metastases, in which the specificity was 100%.
  • [MeSH-major] Benzamides / pharmacokinetics. Iodine Radioisotopes / pharmacokinetics. Melanoma / metabolism. Skin Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11930107.001).
  • [ISSN] 0960-8931
  • [Journal-full-title] Melanoma research
  • [ISO-abbreviation] Melanoma Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Benzamides; 0 / Iodine Radioisotopes; 0 / Melanins; 106790-96-9 / N-(2-(diethylamino)ethyl)-4-iodobenzamide
  •  go-up   go-down


25. Ren G, Miao Z, Liu H, Jiang L, Limpa-Amara N, Mahmood A, Gambhir SS, Cheng Z: Melanin-targeted preclinical PET imaging of melanoma metastasis. J Nucl Med; 2009 Oct;50(10):1692-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Melanin-targeted preclinical PET imaging of melanoma metastasis.
  • Dialkylamino-alkyl-benzamides possess an affinity for melanin, suggesting that labeling of such benzamides with (18)F could potentially produce melanin-targeted PET probes able to identify melanotic melanoma metastases in vivo with high sensitivity and specificity.
  • In vivo distribution and small-animal PET studies were conducted on mice bearing B16F10 melanoma, A375M amelanotic melanoma, and U87MG tumors, and comparative studies were performed with (18)F-FDG PET in the melanoma models.
  • In vivo, (18)F-FBZA displayed significant tumor uptake; at 2 h, 5.94 +/- 1.83 percentage injected dose (%ID) per gram was observed in B16F10 tumors and only 0.75 +/- 0.09 %ID/g and 0.56 +/- 0.13 %ID/g was observed in amelanotic A375M and U87MG tumors, respectively.
  • CONCLUSION: (18)F-FBZA specifically targets primary and metastatic melanotic melanoma lesions with high tumor uptake and may have translational potential.

  • MedlinePlus Health Information. consumer health - Melanoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pigment Cell Res. 2000 Aug;13(4):283-93 [10952398.001]
  • [Cites] J Med Chem. 2000 Oct 19;43(21):3913-22 [11052796.001]
  • [Cites] J Nucl Med. 2001 Feb;42(2):248-56 [11216523.001]
  • [Cites] J Med Chem. 2001 Sep 13;44(19):3132-40 [11543682.001]
  • [Cites] Melanoma Res. 2002 Apr;12(2):115-21 [11930107.001]
  • [Cites] Br J Surg. 2002 Apr;89(4):389-96 [11952577.001]
  • [Cites] Nat Rev Cancer. 2002 Sep;2(9):683-93 [12209157.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2002 Nov;29(11):1478-84 [12397467.001]
  • [Cites] J Med Chem. 2002 Dec 19;45(26):5802-5 [12477363.001]
  • [Cites] Mol Imaging. 2003 Jul;2(3):131-7 [14649056.001]
  • [Cites] J Nucl Med. 2003 Dec;44(12):1927-32 [14660718.001]
  • [Cites] Cancer Res. 2004 Feb 15;64(4):1411-8 [14973076.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Oct 12;101(41):14865-70 [15469923.001]
  • [Cites] Cancer Res. 1984 Mar;44(3):1128-34 [6318981.001]
  • [Cites] Drug Metab Rev. 1984;15(5-6):1183-212 [6396056.001]
  • [Cites] Radiology. 1985 May;155(2):487-92 [3983400.001]
  • [Cites] Pigment Cell Res. 1989 Jan-Feb;2(1):34-9 [2717528.001]
  • [Cites] J Nucl Med. 1989 Mar;30(3):390-7 [2472474.001]
  • [Cites] J Nucl Med. 1991 Aug;32(8):1573-80 [1869982.001]
  • [Cites] Cancer. 1991 Dec 15;68(12):2579-81 [1933805.001]
  • [Cites] Biochem J. 1991 Dec 15;280 ( Pt 3):721-5 [1764036.001]
  • [Cites] J Invest Dermatol. 1993 Jun;100(6):806-11 [8496620.001]
  • [Cites] J Nucl Med. 1993 Aug;34(8):1260-6 [8326382.001]
  • [Cites] J Nucl Med. 1994 Nov;35(11):1741-7 [7965150.001]
  • [Cites] J Nucl Med. 1995 Oct;36(10):1806-10 [7562047.001]
  • [Cites] J Nucl Med. 1997 Jan;38(1):127-33 [8998166.001]
  • [Cites] Anticancer Res. 1997 May-Jun;17(3B):1577-82 [9179197.001]
  • [Cites] Lancet. 2005 Feb 19-25;365(9460):687-701 [15721476.001]
  • [Cites] Cancer Res. 2005 Jun 15;65(12):4979-86 [15958536.001]
  • [Cites] J Nucl Med. 2005 Aug;46(8):1333-41 [16085591.001]
  • [Cites] Cancer Biother Radiopharm. 2006 Apr;21(2):117-29 [16706632.001]
  • [Cites] J Nucl Med. 2006 Jun;47(6):957-67 [16741305.001]
  • [Cites] J Nucl Med. 2007 Jun;48(6):987-94 [17504880.001]
  • [Cites] Surg Oncol Clin N Am. 2007 Apr;16(2):403-30 [17560520.001]
  • [Cites] J Med Chem. 2007 Jul 26;50(15):3561-72 [17602544.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] J Med Chem. 2008 Jun 12;51(11):3133-44 [18481842.001]
  • [Cites] Bioorg Med Chem. 2008 Aug 15;16(16):7671-90 [18656367.001]
  • [Cites] Clin Cancer Res. 2009 Apr 1;15(7):2373-9 [19293257.001]
  • (PMID = 19759116.001).
  • [ISSN] 1535-5667
  • [Journal-full-title] Journal of nuclear medicine : official publication, Society of Nuclear Medicine
  • [ISO-abbreviation] J. Nucl. Med.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P50 CA114747; United States / NCI NIH HHS / CA / R24 CA93862
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Benzamides; 0 / Fluorine Radioisotopes; 0 / Melanins; 0 / Receptors, sigma
  • [Other-IDs] NLM/ NIHMS636087; NLM/ PMC4215196
  •  go-up   go-down


26. Godbole D, Mojamdar M, Pal JK: Increased level of p27 subunit of proteasomes and its co-localization with tyrosinase in amelanotic melanoma cells indicate its direct role in the regulation of melanin biosynthesis. Cell Biol Int; 2006 Nov;30(11):895-902
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased level of p27 subunit of proteasomes and its co-localization with tyrosinase in amelanotic melanoma cells indicate its direct role in the regulation of melanin biosynthesis.
  • Proteasomes have been shown to be involved in the regulation of melanin biosynthesis in melanoma cells.
  • Here we report on the correlation between proteasome subunits and Tyrosinase (Tyr) activity in different cell phenotypes, and thereby regulation of melanin biosynthesis in B16F10 mouse melanoma cells.
  • Our results indicated that the quantity of proteasome subunit p27 is higher and that of the enzyme Tyr and its activity are lower in amelanotic melanoma cells, while the reverse is true in melanotic melanoma cells.
  • Proteasome subunit p27, compared to another subunit p31, shows increased co-localization with Tyr and Tyrosinase related protein 1 (Trp1) in amelanotic cells to a greater extent than that in melanotic cells.
  • On exposure to cycloheximide, increased Tyr degradation was seen in amelanotic cells, as indicated by increased co-localization of p27 and Tyr.
  • Further, exposure of amelanotic melanoma cells with proteasome-specific inhibitor MG132 resulted in an increased Tyr activity, increased levels of Tyr and Trp1, leading to increased melanin synthesis.
  • These results therefore suggest that proteasomes, particularly p27 subunit, are directly involved in the regulation of melanin biosynthesis in mouse melanoma cells.
  • [MeSH-major] Melanins / biosynthesis. Melanoma, Amelanotic / enzymology. Melanoma, Amelanotic / pathology. Monophenol Monooxygenase / metabolism. Proteasome Endopeptidase Complex / metabolism. Protein Subunits / metabolism
  • [MeSH-minor] Animals. Cycloheximide / pharmacology. Enzyme Stability / drug effects. Leupeptins / pharmacology. Mice. Mice, Inbred C57BL. Oxidoreductases / metabolism. Proteasome Inhibitors. Protein Biosynthesis / drug effects. Protein Transport / drug effects

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYCLOHEXIMIDE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16879986.001).
  • [ISSN] 1065-6995
  • [Journal-full-title] Cell biology international
  • [ISO-abbreviation] Cell Biol. Int.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Leupeptins; 0 / Melanins; 0 / Proteasome Inhibitors; 0 / Protein Subunits; 133407-82-6 / benzyloxycarbonylleucyl-leucyl-leucine aldehyde; 98600C0908 / Cycloheximide; EC 1.- / Oxidoreductases; EC 1.14.18.- / tyrosinase-related protein-1; EC 1.14.18.1 / Monophenol Monooxygenase; EC 3.4.25.1 / Proteasome Endopeptidase Complex
  •  go-up   go-down


27. Atjanasuppat K, Wongkham W, Meepowpan P, Kittakoop P, Sobhon P, Bartlett A, Whitfield PJ: In vitro screening for anthelmintic and antitumour activity of ethnomedicinal plants from Thailand. J Ethnopharmacol; 2009 Jun 25;123(3):475-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cytotoxicity of the extracts was evaluated against two cancer cell lines: human amelanotic melanoma (C32) and human cervical carcinoma (HeLa) by the SRB assay.
  • ETHNOPHARMACOLOGICAL RELEVANCE: The plant species screened in this research was recorded by several indigenous medicinal practitioners as antiparasitic, anticancer and/or related activities to the human major organ system.
  • [MeSH-major] Angiosperms. Anthelmintics / therapeutic use. Antineoplastic Agents, Phytogenic / therapeutic use. Plant Extracts / therapeutic use. Plants, Medicinal
  • [MeSH-minor] Animals. Caenorhabditis elegans / drug effects. Cell Line, Tumor. Drug Screening Assays, Antitumor. Female. Fibroblasts / drug effects. Humans. Inhibitory Concentration 50. Medicine, Traditional. Melanoma / drug therapy. Paramphistomatidae / drug effects. Phytotherapy. Schistosoma mansoni / drug effects. Skin Neoplasms / drug therapy. Thailand. Uterine Cervical Neoplasms / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19473794.001).
  • [ISSN] 1872-7573
  • [Journal-full-title] Journal of ethnopharmacology
  • [ISO-abbreviation] J Ethnopharmacol
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Anthelmintics; 0 / Antineoplastic Agents, Phytogenic; 0 / Plant Extracts
  •  go-up   go-down


28. Kozłowska K, Zarzeczna M, Cichorek M: Sensitivity of transplantable melanoma cells to cytokines with regard to their spontaneous apoptosis. Pathobiology; 2001;69(5):249-57
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sensitivity of transplantable melanoma cells to cytokines with regard to their spontaneous apoptosis.
  • OBJECTIVES: Changes in the sensitivity of two lines of transplantable melanoma cells to the antiproliferative activity of interleukin 6 (IL-6), oncostatin M (OSM), tumor necrosis factor-alpha (TNF-alpha) during melanoma progression were the subject of this study.
  • We were looking for a correlation between these changes and the ability of melanoma cells to undergo spontaneous apoptosis.
  • METHODS: The influence of exogenous cytokines on the proliferation of melanoma cells was measured by colorimetric methods with MTT and apoptosis of these cells was estimated by staining with annexin V/propidium iodide, measurement of DNA degradation and cell cycle analysis.
  • RESULTS: It was observed that during melanoma progression the sensitivity of those two melanoma line cells to the antiproliferative effect of IL-6 and OSM did not change, while a spontaneous alteration of the melanotic line into an amelanotic one seemed to be accompanied by resistance of the amelanotic melanoma cells to the antiproliferative activity of TNF-alpha.
  • Simultaneously, we observed a decreased ability of amelanotic melanoma cells (in comparison with the native line) to undergo spontaneous apoptosis.
  • CONCLUSIONS: The observed resistance to the TNF-alpha antiproliferative effect which appears during melanoma progression seems to be correlated with a lower ability of the amelanotic melanoma cells to undergo spontaneous apoptosis.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Apoptosis / drug effects. Cytokines / pharmacology. Melanoma / pathology. Melanoma, Amelanotic / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Animals. Cell Division / drug effects. Cricetinae. DNA Fragmentation / drug effects. Dose-Response Relationship, Drug. Flow Cytometry. Interleukin-6 / pharmacology. Male. Neoplasm Transplantation. Oncostatin M. Peptides / pharmacology. Tetrazolium Salts / metabolism. Thiazoles / metabolism. Tumor Cells, Cultured / drug effects. Tumor Necrosis Factor-alpha / pharmacology

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. METHYLTHIAZOLETETRAZOLIUM .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002 S. Karger AG, Basel
  • (PMID = 12107342.001).
  • [ISSN] 1015-2008
  • [Journal-full-title] Pathobiology : journal of immunopathology, molecular and cellular biology
  • [ISO-abbreviation] Pathobiology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Cytokines; 0 / Interleukin-6; 0 / Peptides; 0 / Tetrazolium Salts; 0 / Thiazoles; 0 / Tumor Necrosis Factor-alpha; 106956-32-5 / Oncostatin M; 298-93-1 / thiazolyl blue
  •  go-up   go-down


29. Menichini F, Tundis R, Loizzo MR, Bonesi M, Provenzano E, de Cindio B, Menichini F: In vitro photo-induced cytotoxic activity of Citrus bergamia and C. medica L. cv. Diamante peel essential oils and identified active coumarins. Pharm Biol; 2010 Sep;48(9):1059-65
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In order to evaluate the cytotoxic activity two melanoma models, such as amelanotic melanoma C32 and malignant melanoma A375, were used.
  • Diamante, respectively and tested for biological activity.
  • This phototoxicity may be considered as a treatment option in some cases of lentigo maligna or lentigo maligna melanoma.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / pharmacology. Antineoplastic Agents, Phytogenic / radiation effects. Citrus / chemistry. Coumarins / pharmacology. Coumarins / radiation effects. Oils, Volatile / pharmacology. Oils, Volatile / radiation effects
  • [MeSH-minor] Cell Line, Tumor. Cell Survival / drug effects. Cell Survival / radiation effects. Drug Discovery. Drug Evaluation, Preclinical. Gas Chromatography-Mass Spectrometry. Humans. Inhibitory Concentration 50. Melanoma / drug therapy. Melanoma, Amelanotic / drug therapy. Methoxsalen / analogs & derivatives. Methoxsalen / analysis. Methoxsalen / chemistry. Methoxsalen / pharmacology. Methoxsalen / radiation effects. Photochemotherapy. Phytotherapy. Time Factors. Ultraviolet Rays

  • Hazardous Substances Data Bank. 8-METHOXYPSORALEN .
  • Hazardous Substances Data Bank. 5-METHOXYPSORALEN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20690896.001).
  • [ISSN] 1744-5116
  • [Journal-full-title] Pharmaceutical biology
  • [ISO-abbreviation] Pharm Biol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Coumarins; 0 / Oils, Volatile; 4FVK84C92X / 5-methoxypsoralen; JWE1QQ247N / 5,7-dimethoxycoumarin; U4VJ29L7BQ / Methoxsalen
  •  go-up   go-down


30. Rigano D, Conforti F, Formisano C, Menichini F, Senatore F: Comparative free radical scavenging potential and cytotoxicity of different extracts from Iris pseudopumila Tineo flowers and rhizomes. Nat Prod Res; 2009;23(1):17-25
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Different Iris species are known as medicinal plants.
  • The chloroform extract from rhizomes demonstrated a good cytotoxic activity against amelanotic melanoma cancer cell line (C32) with an IC(50) of 57 microg mL(-1).
  • [MeSH-major] Antineoplastic Agents, Phytogenic / isolation & purification. Antineoplastic Agents, Phytogenic / pharmacology. Free Radical Scavengers / isolation & purification. Free Radical Scavengers / pharmacology. Iris Plant / chemistry. Plant Extracts / isolation & purification. Plant Extracts / pharmacology. Plants, Medicinal / chemistry
  • [MeSH-minor] Biphenyl Compounds. Drug Screening Assays, Antitumor. Female. Flowers / chemistry. Humans. Inhibitory Concentration 50. Italy. Picrates / pharmacology. Rhizome / chemistry

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19140069.001).
  • [ISSN] 1478-6427
  • [Journal-full-title] Natural product research
  • [ISO-abbreviation] Nat. Prod. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Biphenyl Compounds; 0 / Free Radical Scavengers; 0 / Picrates; 0 / Plant Extracts; 1898-66-4 / 2,2-diphenyl-1-picrylhydrazyl
  •  go-up   go-down


31. Camerin M, Rello-Varona S, Villanueva A, Rodgers MA, Jori G: Metallo-naphthalocyanines as photothermal sensitisers for experimental tumours: in vitro and in vivo studies. Lasers Surg Med; 2009 Nov;41(9):665-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The technique involves the use of high power pulsed laser irradiation and photosensitising agents with especially short lifetime (in the subnanosecond range) in the electronically excited states.
  • STUDY DESIGN/MATERIALS AND METHODS: Two octabutoxy-naphthalocyanines centrally coordinated with Pd(II) or Pt(II) ions were prepared by chemical synthesis and tested for their affinity and photothermal sensitisation activity toward a selected tumour cell line, namely B78H1 amelanotic melanoma.
  • The results thus obtained provided a basis for subsequent in vivo studies, aimed at defining the phototherapeutic efficiency of the two metallo-naphthalocyanines: the photosensitisers were i.v. injected into C57BL/6 mice bearing a subcutaneously transplanted amelanotic melanoma and at 24 hours post-injection the tumour area was irradiated by the Ti:sapphire laser using the same protocol as above detailed.
  • RESULTS: Both naphthalocyanines exhibited a high affinity for the amelanotic melanoma cells.
  • Lastly, both metallo-naphthalocyanines, and in particular the Pd(II) derivative, promoted an important response by the amelanotic melanoma, when the neoplastic tissue was irradiated by the pulsed Ti:sapphire laser.
  • [MeSH-major] Laser Therapy. Melanoma, Amelanotic / radiotherapy. Metalloporphyrins / therapeutic use. Organometallic Compounds / therapeutic use. Photochemotherapy / methods. Skin Neoplasms / radiotherapy
  • [MeSH-minor] Animals. Cell Culture Techniques. Cell Line, Tumor. Female. Mice. Mice, Inbred C57BL. Neoplasm Transplantation. Palladium. Platinum

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. PALLADIUM, ELEMENTAL .
  • Hazardous Substances Data Bank. PLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Wiley-Liss, Inc.
  • (PMID = 19790243.001).
  • [ISSN] 1096-9101
  • [Journal-full-title] Lasers in surgery and medicine
  • [ISO-abbreviation] Lasers Surg Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Metalloporphyrins; 0 / Organometallic Compounds; 0 / palladium 5,9,14,18,23,27,32,36-octabutoxynaphthalocyanine; 49DFR088MY / Platinum; 5TWQ1V240M / Palladium
  •  go-up   go-down


32. Babilas P, Schacht V, Liebsch G, Wolfbeis OS, Landthaler M, Szeimies RM, Abels C: Effects of light fractionation and different fluence rates on photodynamic therapy with 5-aminolaevulinic acid in vivo. Br J Cancer; 2003 May 6;88(9):1462-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Therefore, Syrian Golden hamsters were fitted with dorsal skinfold chambers containing an amelanotic melanoma (n=26).
  • The efficacy was evaluated by measuring the tumour volume of amelanotic melanoma cells grown subcutaneously in the back of Syrian Golden hamsters (n=36).
  • [MeSH-major] Aminolevulinic Acid / therapeutic use. Light. Melanoma, Experimental / drug therapy. Photochemotherapy / methods
  • [MeSH-minor] Animals. Cricetinae. Dose-Response Relationship, Radiation. Mesocricetus. Oxygen Consumption / drug effects. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1997 Jun 15;79(12):2282-308 [9191516.001]
  • [Cites] Cancer Res. 1999 Feb 15;59(4):901-4 [10029082.001]
  • [Cites] J Photochem Photobiol B. 1997 Aug;40(1):76-83 [9301046.001]
  • [Cites] J Photochem Photobiol B. 1997 Oct;40(3):305-12 [9372621.001]
  • [Cites] Adv Exp Med Biol. 1997;428:605-11 [9500105.001]
  • [Cites] Photochem Photobiol. 1998 Apr;67(4):462-6 [9559590.001]
  • [Cites] Surv Ophthalmol. 1997 Nov;42 Suppl 1:S118-26 [9603297.001]
  • [Cites] J Natl Cancer Inst. 1998 Jun 17;90(12):889-905 [9637138.001]
  • [Cites] J Photochem Photobiol B. 1998 Apr;43(1):47-55 [9639914.001]
  • [Cites] Cancer Res. 1999 Dec 15;59(24):6164-70 [10626808.001]
  • [Cites] Cancer Res. 2000 May 15;60(10):2636-42 [10825135.001]
  • [Cites] Photochem Photobiol. 2000 Dec;72(6):794-802 [11140268.001]
  • [Cites] Radiat Res. 2001 Feb;155(2):360-8 [11175672.001]
  • [Cites] J Photochem Photobiol B. 2000 Nov;58(2-3):149-55 [11233643.001]
  • [Cites] Free Radic Res. 2001 Jun;34(6):583-94 [11697034.001]
  • [Cites] Photochem Photobiol. 2001 Nov;74(5):700-6 [11723798.001]
  • [Cites] Photochem Photobiol. 2002 Apr;75(4):382-91 [12003128.001]
  • [Cites] Lasers Med Sci. 2002;17(2):101-9 [12111593.001]
  • [Cites] Arch Dermatol Res. 2002 Nov;294(8):341-8 [12420102.001]
  • [Cites] Microvasc Res. 1977 May;13(3):399-408 [327212.001]
  • [Cites] Res Exp Med (Berl). 1980;177(2):125-34 [7003665.001]
  • [Cites] Cancer Res. 1981 May;41(5):2008-13 [7214369.001]
  • [Cites] J Photochem Photobiol B. 1998 Dec;47(2-3):121-8 [10093911.001]
  • [Cites] J Invest Dermatol. 1999 May;112(5):723-8 [10233763.001]
  • [Cites] J Pathol Bacteriol. 1963 Jul;86:99-102 [14019186.001]
  • [Cites] Neuropharmacology. 1984 Apr;23(4):477-81 [6728134.001]
  • [Cites] Lab Anim. 1988 Jul;22(3):195-201 [3172698.001]
  • [Cites] Cancer Chemother Pharmacol. 1989;24(3):148-54 [2544306.001]
  • [Cites] Cancer Res. 1989 Dec 1;49(23):6449-65 [2684393.001]
  • [Cites] Cancer Res. 1990 Nov 15;50(22):7236-41 [2171760.001]
  • [Cites] Ultrasound Med Biol. 1990;16(6):595-605 [2238268.001]
  • [Cites] J Natl Cancer Inst. 1993 Mar 17;85(6):443-56 [8445672.001]
  • [Cites] Lancet. 1993 Jul 17;342(8864):147-8 [7687318.001]
  • [Cites] Photochem Photobiol. 1994 Jan;59(1):73-6 [8127943.001]
  • [Cites] Br J Cancer. 1994 Nov;70(5):826-33 [7947087.001]
  • [Cites] Drugs. 1994 Oct;48(4):510-27 [7528127.001]
  • [Cites] Cancer Res. 1995 Apr 15;55(8):1723-31 [7712481.001]
  • [Cites] Photochem Photobiol. 1995 May;61(5):523-8 [7770514.001]
  • [Cites] Neoplasma. 1995;42(3):109-13 [7637818.001]
  • [Cites] Br J Cancer. 1995 Sep;72(3):589-94 [7669566.001]
  • [Cites] J Invest Dermatol. 1995 Nov;105(5):672-7 [7594642.001]
  • [Cites] Br J Cancer. 1995 Nov;72(5):1125-30 [7577457.001]
  • [Cites] Urol Int. 1995;55(4):190-6 [8588264.001]
  • [Cites] J Surg Oncol. 1996 Jun;62(2):109-14 [8649036.001]
  • [Cites] Br J Cancer. 1996 Oct;74(8):1206-15 [8883406.001]
  • [Cites] Photochem Photobiol. 1997 Jul;66(1):114-8 [9230710.001]
  • (PMID = 12778078.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 88755TAZ87 / Aminolevulinic Acid
  • [Other-IDs] NLM/ PMC2741044
  •  go-up   go-down


33. Juzenas P, Juzeniene A, Iani V, Moan J: Depth profile of protoporphyrin IX fluorescence in an amelanotic mouse melanoma model. Photochem Photobiol; 2009 May-Jun;85(3):760-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Depth profile of protoporphyrin IX fluorescence in an amelanotic mouse melanoma model.
  • Protoporphyrin IX (PpIX) fluorescence was measured at different depths in a subcutaneous amelanotic melanoma model (LOX) in mice.
  • PpIX was induced by topical application of 5-aminolevulinic acid (ALA) and two of its derivatives, the methylester (MAL) and hexylester (HAL) onto the normal skin covering the tumor.
  • Using the estimated diffusion coefficients for topically applied ALA (0.16 +/- 0.03 mm(2) h(-1)), MAL (0.045 +/- 0.005 mm(2) h(-1)) and HAL (0.037 +/- 0.003 mm(2) h(-1)), the behavior of the drugs after different application times could be estimated in this tumor model.
  • [MeSH-major] Melanoma, Experimental / metabolism. Protoporphyrins / metabolism
  • [MeSH-minor] Animals. Disease Models, Animal. Female. Fluorescence. Mice. Mice, Inbred BALB C

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19140894.001).
  • [ISSN] 0031-8655
  • [Journal-full-title] Photochemistry and photobiology
  • [ISO-abbreviation] Photochem. Photobiol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Protoporphyrins; 553-12-8 / protoporphyrin IX
  •  go-up   go-down


34. Traynor NJ, McKenzie RC, Beckett GJ, Gibbs NK: Selenomethionine inhibits ultraviolet radiation-induced p53 transactivation. Photodermatol Photoimmunol Photomed; 2006 Dec;22(6):297-303
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Ultraviolet (UV) radiation damages the cellular DNA of skin cells.
  • In response, wild-type p53 protein accumulates in irradiated cells and the stabilized and transactivated protein can then induce genes involved in cell cycle arrest in G1, or in the initiation of apoptosis.
  • METHODS: We examined whether selenomethionine could protect human skin cells from UV radiation-induced p53 transactivation, using a pRGCDeltafos-lacZ p53-dependent reporter construct stably transfected in an amelanotic melanoma cell line (Arn-8) which expresses wild-type p53.
  • [MeSH-major] Radiation-Protective Agents / pharmacology. Selenomethionine / pharmacology. Skin / drug effects. Skin / radiation effects. Ultraviolet Rays
  • [MeSH-minor] Apoptosis / drug effects. Cell Division. Cell Line, Tumor / drug effects. Cell Line, Tumor / metabolism. Cell Line, Tumor / radiation effects. Dose-Response Relationship, Drug. Dose-Response Relationship, Radiation. Humans. Tumor Suppressor Protein p53 / metabolism

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. SELENIUM METHIONINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17100737.001).
  • [ISSN] 0905-4383
  • [Journal-full-title] Photodermatology, photoimmunology & photomedicine
  • [ISO-abbreviation] Photodermatol Photoimmunol Photomed
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Radiation-Protective Agents; 0 / Tumor Suppressor Protein p53; 964MRK2PEL / Selenomethionine
  •  go-up   go-down


35. Hiratsuka J, Kondoh H, Tsuboi T, Yoshino K, Imajo Y, Mishima Y: Selective uptake of para-boronophenylalanine increases in amelanotic melanoma cells transfected by the tyrosinase gene. Melanoma Res; 2000 Jun;10(3):297-302
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Selective uptake of para-boronophenylalanine increases in amelanotic melanoma cells transfected by the tyrosinase gene.
  • To investigate the mechanism of uptake of para-boronophenylalanine (p-BPA), a capture agent for boron neutron capture therapy (BNCT) of melanoma and brain tumour, into melanoma cells, we studied the relationship between melanin synthesis and the concentration of boron using tyrosinase-deficient mouse amelanotic melanoma cells (A1059) and melanotic melanoma cells (TA1059).
  • The order of p-BPA uptake was TA1059 > B16F10 > A1059 at the time points examined, and the boron content of TA1059 was approximately 1.5-fold higher than that of B16F10.
  • Our experimental findings indicated that melanin synthesis is a very important factor for characterizing the increase in accumulation of p-BPA in melanoma cells.
  • The difference in accumulation of p-BPA and m-BPA could be due to differences in the properties of p-BPA as a tyrosine analogue needed for melanin synthesis.
  • [MeSH-major] Boron Compounds / pharmacokinetics. Gene Expression. Melanoma, Amelanotic / genetics. Melanoma, Amelanotic / metabolism. Monophenol Monooxygenase / genetics. Phenylalanine / analogs & derivatives. Phenylalanine / pharmacokinetics. Radiation-Sensitizing Agents / pharmacokinetics. Transfection
  • [MeSH-minor] Animals. Humans. Melanins / biosynthesis. Melanoma, Experimental / metabolism. Mice. Tumor Cells, Cultured

  • Hazardous Substances Data Bank. BORON COMPOUNDS .
  • Hazardous Substances Data Bank. (L)-Phenylalanine .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10890385.001).
  • [ISSN] 0960-8931
  • [Journal-full-title] Melanoma research
  • [ISO-abbreviation] Melanoma Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] ENGLAND
  • [Chemical-registry-number] 0 / Boron Compounds; 0 / Melanins; 0 / Radiation-Sensitizing Agents; 47E5O17Y3R / Phenylalanine; EC 1.14.18.1 / Monophenol Monooxygenase; UID84303EL / 4-boronophenylalanine
  •  go-up   go-down


36. Camerin M, Rodgers MA, Kenney ME, Jori G: Photothermal sensitisation: evidence for the lack of oxygen effect on the photosensitising activity. Photochem Photobiol Sci; 2005 Mar;4(3):251-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Irradiation of amelanotic melanoma B78H1 cells in the presence of liposome-delivered Ni(II)-octabutoxy-naphthalocyanine with a Q-switched Ti:sapphire laser operated in a pulsed mode (850 nm, 30 ns pulses, 10 Hz, 120 mJ pulse -1) promotes a photothermal sensitization process leading to extensive cell inactivation.
  • [MeSH-minor] Air. Animals. Cell Line, Tumor. Lasers. Melanoma, Experimental / drug therapy. Metalloporphyrins / therapeutic use. Mice. Nitrogen. Time Factors

  • Hazardous Substances Data Bank. Nitrogen, Elemental .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15738991.001).
  • [ISSN] 1474-905X
  • [Journal-full-title] Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology
  • [ISO-abbreviation] Photochem. Photobiol. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Metalloporphyrins; 0 / octabutoxynaphthalocyaninenickel(II); N762921K75 / Nitrogen
  •  go-up   go-down


37. Cichorek M, Kozłowska K, Bryl E: Mitochondrial transmembrane potential in spontaneous and camptothecin-induced apoptosis of melanotic and amelanotic melanoma cells. Neoplasma; 2007;54(1):29-36
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mitochondrial transmembrane potential in spontaneous and camptothecin-induced apoptosis of melanotic and amelanotic melanoma cells.
  • In this work we tried to estimate the role of mitochondria in the ability of cells of two: melanotic and amelanotic transplantable melanoma lines to undergo spontaneous and camptothecin-induced apoptosis.
  • Cytochrome c release and PARP cleavage as the biological effects of DeltaPsim changes belonging to the phenomena observed during apoptosis were estimated by Western blotting.
  • The results of our investigations showed in both transplantable melanoma cells the features indicating apoptosis: DeltaPsi changes, cytochrome c release and PARP cleavage, but the degree of observed changes depended on the phenotype of melanoma cells examined.
  • After camptothecin treatment the changes were more pronounced in the amelanotic melanoma cells- the more aggressive line.
  • [MeSH-major] Apoptosis / drug effects. Camptothecin / pharmacology. Membrane Potential, Mitochondrial / drug effects
  • [MeSH-minor] Animals. Antineoplastic Agents, Phytogenic / pharmacology. Blotting, Western. Cricetinae. Cytochromes c / secretion. Cytosol / drug effects. Cytosol / metabolism. Flow Cytometry. Male. Melanoma / metabolism. Melanoma / pathology. Melanoma / physiopathology. Mesocricetus. Poly(ADP-ribose) Polymerases / metabolism. Time Factors. Tumor Cells, Cultured

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17203890.001).
  • [ISSN] 0028-2685
  • [Journal-full-title] Neoplasma
  • [ISO-abbreviation] Neoplasma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Slovakia
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 9007-43-6 / Cytochromes c; EC 2.4.2.30 / Poly(ADP-ribose) Polymerases; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


38. Allen RG, Balin AK: Effects of oxygen on the antioxidant responses of normal and transformed cells. Exp Cell Res; 2003 Oct 1;289(2):307-16
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Exposure to hyperoxia generally failed to induce either the activity of GSH peroxidase (GPx) or the manganese-containing form of superoxide dismutase (MnSOD) after 48 h, although at 605 mm Hg oxygen, small inductions of MnSOD activity were observed in adult lung fibroblasts and amelanotic melanoma.
  • [MeSH-minor] Anoxia / metabolism. Anoxia / physiopathology. Cell Line, Transformed. Epithelial Cells / drug effects. Epithelial Cells / metabolism. Female. Fibroblasts / drug effects. Fibroblasts / metabolism. Glutathione / drug effects. Glutathione / metabolism. Glutathione Peroxidase / metabolism. Humans. Hyperoxia / metabolism. Male. Paraquat / pharmacology. Superoxide Dismutase / metabolism

  • MedlinePlus Health Information. consumer health - Antioxidants.
  • Hazardous Substances Data Bank. Paraquat .
  • Hazardous Substances Data Bank. OXYGEN .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14499631.001).
  • [ISSN] 0014-4827
  • [Journal-full-title] Experimental cell research
  • [ISO-abbreviation] Exp. Cell Res.
  • [Language] eng
  • [Grant] United States / NIA NIH HHS / AG / AG00282; United States / NIA NIH HHS / AG / AG04993; United States / NCRR NIH HHS / RR / RR00102
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antioxidants; EC 1.11.1.9 / Glutathione Peroxidase; EC 1.15.1.1 / Superoxide Dismutase; GAN16C9B8O / Glutathione; PLG39H7695 / Paraquat; S88TT14065 / Oxygen
  •  go-up   go-down


39. Said A, Tundis R, Hawas UW, El-Kousy SM, Rashed K, Menichini F, Bonesi M, Huefner A, Loizzo MR, Menichinib F: In vitro antioxidant and antiproliferative activities of flavonoids from Ailanthus excelsa (Roxb.) (Simaroubaceae) leaves. Z Naturforsch C; 2010 Mar-Apr;65(3-4):180-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The present study aimed to investigate the chemical composition, and the antioxidant and antiproliferative activities of Ailanthus excelsa, a plant used in Egyptian traditional medicine.
  • Compounds 1 and 3 inhibited cell growth in both amelanotic melanoma and malignant melanoma cells.
  • [MeSH-minor] Biphenyl Compounds / chemistry. Cell Division / drug effects. Cell Line, Tumor / drug effects. Cell Line, Tumor / pathology. Egypt. Fibroblasts / cytology. Fibroblasts / drug effects. Fibroblasts / physiology. Free Radical Scavengers / isolation & purification. Free Radical Scavengers / pharmacology. Humans. Oxidation-Reduction. Picrates / chemistry. Skin

  • MedlinePlus Health Information. consumer health - Antioxidants.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20469635.001).
  • [ISSN] 0939-5075
  • [Journal-full-title] Zeitschrift für Naturforschung. C, Journal of biosciences
  • [ISO-abbreviation] Z. Naturforsch., C, J. Biosci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antioxidants; 0 / Biphenyl Compounds; 0 / Flavonoids; 0 / Free Radical Scavengers; 0 / Picrates; 1898-66-4 / 2,2-diphenyl-1-picrylhydrazyl
  •  go-up   go-down


40. Chen KG, Leapman RD, Zhang G, Lai B, Valencia JC, Cardarelli CO, Vieira WD, Hearing VJ, Gottesman MM: Influence of melanosome dynamics on melanoma drug sensitivity. J Natl Cancer Inst; 2009 Sep 16;101(18):1259-71
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Influence of melanosome dynamics on melanoma drug sensitivity.
  • BACKGROUND: Malignant melanomas are intrinsically resistant to many conventional treatments, such as radiation and chemotherapy, for reasons that are poorly understood.
  • Here we propose and test a model that explains drug resistance or sensitivity in terms of melanosome dynamics.
  • METHODS: The growth and sensitivity to cisplatin of MNT-1 cells, which are melanotic and enriched with mature stage III and IV melanosomes, and SK-MEL-28 cells, which have only immature stage I and II melanosomes, were compared using clonogenic assays.
  • The relationship between drug transporter function and endogenous melanogenic toxicity was assessed by treating cells with the cyclosporin analog PSC-833 and by assessing vacuole formation and cell growth inhibition.
  • RESULTS: Endogenous melanogenic cytotoxicity, produced by damaged melanosomes, resulted in pronounced cell growth inhibition in MNT-1 cells compared with amelanotic SK-MEL-28 cells.
  • CONCLUSIONS: Melanosome dynamics (including their biogenesis, density, status, and structural integrity) regulate the drug resistance of melanoma cells.
  • Manipulation of melanosome functions may be an effective way to enhance the therapeutic activity of anticancer drugs against melanoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / pharmacology. Drug Resistance, Neoplasm. Melanoma / drug therapy. Melanoma / pathology. Melanosomes / drug effects. Melanosomes / ultrastructure. Skin Neoplasms / drug therapy. Skin Neoplasms / pathology
  • [MeSH-minor] Animals. Cell Death / drug effects. Cell Line, Tumor. Cisplatin / pharmacology. Cyclosporins / pharmacology. Doxorubicin / pharmacology. Fluorescent Antibody Technique, Indirect. Humans. Melanoma, Experimental / drug therapy. Melanoma, Experimental / pathology. Mice. Microscopy, Confocal. Microscopy, Electron. Verapamil / pharmacology. Vinblastine / pharmacology

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. VERAPAMIL HYDROCHLORIDE .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 2002 Jan 25;277(4):2505-10 [11700317.001]
  • [Cites] Blood. 2001 Dec 1;98(12):3212-20 [11719356.001]
  • [Cites] Mol Biol Cell. 2002 Jun;13(6):1953-64 [12058062.001]
  • [Cites] J Invest Dermatol. 2002 Jun;118(6):923-32 [12060385.001]
  • [Cites] Mol Biol Cell. 2002 Dec;13(12):4206-20 [12475946.001]
  • [Cites] Oncogene. 2003 May 19;22(20):3138-51 [12789290.001]
  • [Cites] J Invest Dermatol. 2003 Jul;121(1):172-6 [12839578.001]
  • [Cites] J Biol Chem. 2003 Nov 21;278(47):47156-65 [12960149.001]
  • [Cites] J Biol Chem. 2004 Jan 2;279(1):288-98 [14576150.001]
  • [Cites] Oncogene. 2004 Jan 8;23(1):30-8 [14712208.001]
  • [Cites] Exp Cell Res. 2004 Aug 15;298(2):317-28 [15265682.001]
  • [Cites] Clin Cancer Res. 2004 Jul 15;10(14):4724-33 [15269145.001]
  • [Cites] Cancer Cell. 2004 Aug;6(2):129-37 [15324696.001]
  • [Cites] N Engl J Med. 2004 Sep 2;351(10):998-1012 [15342808.001]
  • [Cites] In Vitro Cell Dev Biol. 1987 Jul;23(7):519-22 [3610949.001]
  • [Cites] Ann Clin Lab Sci. 1990 Nov-Dec;20(6):379-84 [2073087.001]
  • [Cites] Cancer Res. 1994 Sep 15;54(18):4980-7 [7915196.001]
  • [Cites] J Biol Chem. 1997 Feb 28;272(9):5974-82 [9038218.001]
  • [Cites] Cancer Chemother Pharmacol. 1997;40 Suppl:S13-9 [9272128.001]
  • [Cites] J Natl Cancer Inst. 2004 Nov 17;96(22):1702-13 [15547183.001]
  • [Cites] J Dermatol Sci. 2005 Jan;37(1):3-14 [15619429.001]
  • [Cites] Pigment Cell Res. 2005 Apr;18(2):102-12 [15760339.001]
  • [Cites] Cancer Res. 2005 Oct 15;65(20):9328-37 [16230395.001]
  • [Cites] Nat Rev Drug Discov. 2006 Mar;5(3):219-34 [16518375.001]
  • [Cites] Front Biosci. 2006;11:2157-73 [16720302.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jun 27;103(26):9903-7 [16777967.001]
  • [Cites] J Clin Oncol. 2006 Jul 1;24(19):3157-63 [16809738.001]
  • [Cites] Genes Dev. 2006 Aug 15;20(16):2149-82 [16912270.001]
  • [Cites] Science. 2006 Oct 6;314(5796):126-9 [16946036.001]
  • [Cites] J Biol Chem. 2007 Apr 13;282(15):11266-80 [17303571.001]
  • [Cites] Nature. 2007 Apr 12;446(7137):745-7 [17429391.001]
  • [Cites] Cancer Res. 2009 Feb 1;69(3):992-9 [19155314.001]
  • [Cites] Melanoma Res. 2000 Oct;10(5):499-505 [11095412.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10698-703 [11526213.001]
  • [Cites] Melanoma Res. 2001 Oct;11(5):469-76 [11595883.001]
  • [Cites] FASEB J. 2001 Oct;15(12):2149-61 [11641241.001]
  • [Cites] Traffic. 2002 Apr;3(4):237-48 [11929605.001]
  • (PMID = 19704071.001).
  • [ISSN] 1460-2105
  • [Journal-full-title] Journal of the National Cancer Institute
  • [ISO-abbreviation] J. Natl. Cancer Inst.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / Z99 NS999999
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cyclosporins; 121584-18-7 / valspodar; 5V9KLZ54CY / Vinblastine; 80168379AG / Doxorubicin; CJ0O37KU29 / Verapamil; Q20Q21Q62J / Cisplatin
  • [Other-IDs] NLM/ PMC2744727
  •  go-up   go-down


41. Halaban R, Patton RS, Cheng E, Svedine S, Trombetta ES, Wahl ML, Ariyan S, Hebert DN: Abnormal acidification of melanoma cells induces tyrosinase retention in the early secretory pathway. J Biol Chem; 2002 Apr 26;277(17):14821-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Abnormal acidification of melanoma cells induces tyrosinase retention in the early secretory pathway.
  • In tyrosinase-positive amelanotic melanoma cells, inactive tyrosinase accumulates in the endoplasmic reticulum.
  • Based on studies described here, we propose that aberrant vacuolar proton ATPase (V-ATPase)-mediated proton transport in melanoma cells disrupts tyrosinase trafficking through the secretory pathway.
  • Amelanotic but not melanotic melanoma cells or normal melanocytes display elevated proton export as observed by the acidification of the extracellular medium and their ability to maintain neutral intracellular pH.
  • Tyrosinase activity and transit through the Golgi were restored by either maintaining the melanoma cells in alkaline medium (pH 7.4-7.7) or by restricting glucose uptake.
  • Because it was previously shown that V-ATPase activity is increased in solid tumors in response to an acidified environment, the appearance of hypopigmented cells in tyrosinase-positive melanoma tumors may indicate the onset of enhanced glycolysis and extracellular acidification, conditions known to favor metastatic spread and resistance to weak base chemotherapeutic drugs.
  • [MeSH-major] Acids / metabolism. Macrolides. Melanoma / metabolism. Monophenol Monooxygenase / metabolism
  • [MeSH-minor] Anti-Bacterial Agents / pharmacology. Cells, Cultured. Endoplasmic Reticulum / enzymology. Endoplasmic Reticulum / metabolism. Enzyme Inhibitors / pharmacology. Glucose / metabolism. Golgi Apparatus / enzymology. Golgi Apparatus / metabolism. Humans. Hydrogen-Ion Concentration. Tumor Cells, Cultured. Vacuolar Proton-Translocating ATPases / antagonists & inhibitors. Vacuolar Proton-Translocating ATPases / metabolism

  • MedlinePlus Health Information. consumer health - Melanoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. GLUCOSE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11812790.001).
  • [ISSN] 0021-9258
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] eng
  • [Grant] United States / NIAMS NIH HHS / AR / AR39848; United States / NIAMS NIH HHS / AR / AR41942; United States / NCI NIH HHS / CA / CA44542; United States / NCI NIH HHS / CA / CA79864
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Acids; 0 / Anti-Bacterial Agents; 0 / Enzyme Inhibitors; 0 / Macrolides; 80890-47-7 / concanamycin A; 88899-55-2 / bafilomycin A1; EC 1.14.18.1 / Monophenol Monooxygenase; EC 3.6.1.- / Vacuolar Proton-Translocating ATPases; IY9XDZ35W2 / Glucose
  •  go-up   go-down


42. Tundis R, Loizzo MR, Bonesi M, Menichini F, Dodaro D, Passalacqua NG, Statti G, Menichini F: In vitro cytotoxic effects of Senecio stabianus Lacaita (Asteraceae) on human cancer cell lines. Nat Prod Res; 2009;23(18):1707-18
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This study is aimed to evaluate the in vitro cytotoxicity of Senecio stabianus Lacaita (Asteraceae) against renal adenocarcinoma ACHN, hormone-dependent prostate carcinoma LNCaP, amelanotic melanoma C32 and human breast adenocarcinoma MCF-7 cell lines.
  • The n-hexane extract showed an interesting activity with IC(50) values of 62.7 and 71.1 microg mL(-1) against C32 and LNCaP, respectively.
  • Two compounds identified in the n-hexane extract, linalool and beta-caryophyllene, were found to be active against C32 cells (IC(50) values of 23.2 and 20.1 microg mL(-1), respectively).
  • [MeSH-minor] Cell Line, Tumor. Cell Proliferation / drug effects. Cell Survival / drug effects. Gas Chromatography-Mass Spectrometry. Hexanes / chemistry. Humans. Monoterpenes / chemistry. Monoterpenes / pharmacology. Pyrrolizidine Alkaloids / chemistry. Pyrrolizidine Alkaloids / pharmacology. Sesquiterpenes / chemistry. Sesquiterpenes / pharmacology

  • Hazardous Substances Data Bank. N-HEXANE .
  • Hazardous Substances Data Bank. LINALOOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19921589.001).
  • [ISSN] 1478-6427
  • [Journal-full-title] Natural product research
  • [ISO-abbreviation] Nat. Prod. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Hexanes; 0 / Monoterpenes; 0 / Plant Extracts; 0 / Pyrrolizidine Alkaloids; 0 / Sesquiterpenes; 2DDG612ED8 / n-hexane; 54W56MD2WD / humulene; BHW853AU9H / caryophyllene; D81QY6I88E / linalool
  •  go-up   go-down


43. Loizzo MR, Tundis R, Menichini F, Saab AM, Statti GA, Menichini F: Antiproliferative effects of essential oils and their major constituents in human renal adenocarcinoma and amelanotic melanoma cells. Cell Prolif; 2008 Dec;41(6):1002-1012
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Antiproliferative effects of essential oils and their major constituents in human renal adenocarcinoma and amelanotic melanoma cells.
  • Antiproliferative activity was tested on amelanotic melanoma C32 cells and on renal cell adenocarcinoma cells, using the sulphorhodamine B assay.
  • RESULTS: Cupressus sempervirens ssp. pyramidalis leaf oil exerted the highest cytotoxic activity with an IC(50)value of 104.90 microg/mL against C32, followed by activity of P. orientalis and P. asperula on the renal adenocarcinoma cell line (IC(50) of 121.93 and 139.17 microg/mL, respectively). P. orientalis essential oil was also active against amelanotic melanoma with an IC(50) of 330.04 microg/mL.
  • Interestingly, beta-caryophyllene and linalool exhibited comparable IC(50) values to the commercial drug vinblastine on the ACHN cell line.
  • [MeSH-major] Carcinoma, Renal Cell / drug therapy. Carcinoma, Renal Cell / pathology. Kidney Neoplasms / drug therapy. Melanoma, Amelanotic / drug therapy. Melanoma, Amelanotic / pathology. Oils, Volatile / therapeutic use. Skin Neoplasms / drug therapy
  • [MeSH-minor] Cell Death / drug effects. Cell Line. Cell Proliferation / drug effects. Cupressus / chemistry. Dose-Response Relationship, Drug. Drug Screening Assays, Antitumor. Humans. Phytotherapy. Plant Oils / chemistry. Plant Oils / pharmacology. Plant Oils / therapeutic use. Terpenes / pharmacology

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19040575.001).
  • [ISSN] 1365-2184
  • [Journal-full-title] Cell proliferation
  • [ISO-abbreviation] Cell Prolif.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Oils, Volatile; 0 / Plant Oils; 0 / Terpenes
  •  go-up   go-down


44. Jezek P, Nekvasil M, Skobisová E, Urbánková E, Jirsa M, Zadinová M, Poucková P, Klepácek I: Experimental photodynamic therapy with MESO-tetrakisphenylporphyrin (TPP) in liposomes leads to disintegration of human amelanotic melanoma implanted to nude mice. Int J Cancer; 2003 Feb 20;103(5):693-702
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Experimental photodynamic therapy with MESO-tetrakisphenylporphyrin (TPP) in liposomes leads to disintegration of human amelanotic melanoma implanted to nude mice.
  • Liposomal meso-tetrakis-phenylporphyrin (TPP) was tested for photodynamic therapy (PDT) of human amelanotic melanomas implanted in nude mice.
  • Melanoma remissions were accompanied by tumour surface necroses and were documented by the appearance of nontumourous cells with nonpycnotic nuclei.
  • Consequently, liposomal TPP is suggested as a potentially suitable efficient preparation for PDT.
  • [MeSH-major] Melanoma, Amelanotic / drug therapy. Melanoma, Experimental / drug therapy. Photochemotherapy. Photosensitizing Agents / therapeutic use. Porphyrins / therapeutic use. Skin Neoplasms / drug therapy
  • [MeSH-minor] Animals. Drug Carriers. Female. Humans. Injections, Intralesional. Injections, Intravenous. Liposomes. Mice. Mice, Nude. Microscopy, Fluorescence

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002 Wiley-Liss, Inc.
  • (PMID = 12494481.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Drug Carriers; 0 / Liposomes; 0 / Photosensitizing Agents; 0 / Porphyrins; 0 / meso-tetrakis(4-sulfonatophenyl)porphyrin
  •  go-up   go-down


45. Bonesi M, Tundis R, Deguin B, Loizzo MR, Menichini F, Tillequin F, Menichini F: In vitro biological evaluation of novel 7-O-dialkylaminoalkyl cytotoxic pectolinarigenin derivatives against a panel of human cancer cell lines. Bioorg Med Chem Lett; 2008 Oct 15;18(20):5431-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In vitro biological evaluation of novel 7-O-dialkylaminoalkyl cytotoxic pectolinarigenin derivatives against a panel of human cancer cell lines.
  • The effect of novel pectolinarigenin derivatives bearing a dialkylaminoalkyl substituent at O-7 on cell proliferation was evaluated in vitro in a panel of seven human cancer cell lines including renal adenocarcinoma ACHN, amelanotic melanoma C32, colorectal adenocarcinoma Caco-2, lung large cell carcinoma COR-L23, malignant melanoma A375, lung carcinoma A549 and hepatocellular carcinoma Huh-7D12 cell lines.
  • None of the tested compounds affected the proliferation of skin fibroblasts 142BR suggesting a selective activity against tumor cells.
  • [MeSH-major] Antineoplastic Agents / chemical synthesis. Chemistry, Pharmaceutical / methods. Chromones / chemistry. Drug Screening Assays, Antitumor
  • [MeSH-minor] Caco-2 Cells. Cell Line, Tumor. Cell Proliferation. Drug Design. Flavones / chemistry. Humans. In Vitro Techniques. Inhibitory Concentration 50. Models, Chemical. Rhodamines / chemistry

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18818071.001).
  • [ISSN] 1464-3405
  • [Journal-full-title] Bioorganic & medicinal chemistry letters
  • [ISO-abbreviation] Bioorg. Med. Chem. Lett.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Chromones; 0 / Flavones; 0 / Rhodamines; 0 / pectolinarigenin; 2609-88-3 / lissamine rhodamine B
  •  go-up   go-down


46. Koszałka P, Szmit E, Myśliwski A, Bigda J: Anti-tumor action of tumor necrosis factor against Bomirski Ab melanoma in hamsters. Arch Immunol Ther Exp (Warsz); 2007 Jul-Aug;55(4):267-79
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anti-tumor action of tumor necrosis factor against Bomirski Ab melanoma in hamsters.
  • MATERIALS AND METHODS: The effects of intratumoral injection of rat TNF into hamsters bearing Bomirski Ab amelanotic melanoma, a fast growing tumor of high metastatic potential, were tested.
  • Moreover, the synergistic anti-tumor effect of TNF and anti-angiogenic agent TNP-470 suggested a cooperative activity of both substances on tumor vasculature.
  • In vitro assays indicated a direct cytotoxic effect of TNF against Ab melanoma cells, most probably as an outcome of apoptosis.
  • Intratumoral application of TNF also caused some modulation of cytokine response in melanoma-bearing hamsters as evidenced by increased levels of IL-6 in blood serum.
  • CONCLUSIONS: This study established Bomirski Ab melanoma as a useful model for complex analysis of the anti-tumor activity of TNF.
  • [MeSH-major] Angiogenesis Inhibitors / metabolism. Melanoma, Experimental / metabolism. Neovascularization, Pathologic / metabolism. Recombinant Proteins / metabolism. Tumor Necrosis Factor-alpha / metabolism
  • [MeSH-minor] Animals. Cell Line, Tumor. Cell Survival / drug effects. Cricetinae. Cyclohexanes / administration & dosage. Dose-Response Relationship, Drug. Drug Synergism. Injections, Intralesional. Injections, Subcutaneous. Interleukin-6 / blood. Killer Cells, Natural / metabolism. Macrophages / metabolism. Male. Mesocricetus. Necrosis. Neoplasm Metastasis. Rats. Sesquiterpenes / administration & dosage. Time Factors

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neoplasma. 1995;42(1):15-9 [7617068.001]
  • [Cites] Int J Cancer. 1996 May 3;66(3):388-92 [8621262.001]
  • [Cites] Eur Cytokine Netw. 1996 Apr-Jun;7(2):93-124 [8688493.001]
  • [Cites] Cancer Immunol Immunother. 1996 May;42(4):231-6 [8665570.001]
  • [Cites] Immunol Cell Biol. 1996 Apr;74(2):151-8 [8724002.001]
  • [Cites] Br J Cancer. 1996 Dec;74(12):1908-15 [8980389.001]
  • [Cites] Biochem Biophys Res Commun. 1987 Mar 30;143(3):997-1004 [2436621.001]
  • [Cites] J Biol Chem. 1987 May 25;262(15):6951-4 [3034874.001]
  • [Cites] J Immunol. 1987 Jun 15;138(12):4185-91 [3108384.001]
  • [Cites] Virchows Arch B Cell Pathol Incl Mol Pathol. 1987;52(6):489-500 [2884771.001]
  • [Cites] Virchows Arch B Cell Pathol Incl Mol Pathol. 1987;53(6):353-8 [2891219.001]
  • [Cites] J Exp Med. 1988 Mar 1;167(3):1067-85 [3351434.001]
  • [Cites] J Exp Med. 1988 Mar 1;167(3):1086-99 [3258350.001]
  • [Cites] J Immunol. 1988 Jun 1;140(11):4056-61 [3372997.001]
  • [Cites] Cancer Metastasis Rev. 1988 Jun;7(2):95-118 [3293837.001]
  • [Cites] J Exp Med. 1988 Aug 1;168(2):637-47 [3411290.001]
  • [Cites] Cancer Res. 1988 Oct 1;48(19):5417-21 [3262009.001]
  • [Cites] Cancer Immunol Immunother. 1988;27(2):128-32 [2458181.001]
  • [Cites] Int J Cancer. 1988 Sep 15;42(3):395-9 [3417368.001]
  • [Cites] J Immunol. 1988 Oct 15;141(8):2629-34 [3171180.001]
  • [Cites] Cancer Lett. 1989 Jan;44(1):67-72 [2917343.001]
  • [Cites] Anticancer Res. 1997 May-Jun;17(3C):2207-11 [9216689.001]
  • [Cites] Anticancer Res. 1998 Jan-Feb;18(1A):441-3 [9568116.001]
  • [Cites] Infect Immun. 1998 May;66(5):2135-42 [9573100.001]
  • [Cites] Neoplasma. 1998;45(3):162-8 [9717529.001]
  • [Cites] Oncogene. 1999 Feb 25;18(8):1553-9 [10102625.001]
  • [Cites] Ann Surg. 2004 Dec;240(6):939-47; discussion 947-8 [15570199.001]
  • [Cites] Jpn J Cancer Res. 1989 Dec;80(12):1161-4 [2516844.001]
  • [Cites] J Immunol. 1990 Nov 1;145(9):2902-7 [2120340.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Jun 6;97(12):6427-32 [10841547.001]
  • [Cites] J Interferon Cytokine Res. 2001 Jul;21(7):475-84 [11506741.001]
  • [Cites] Cell Signal. 2002 Jun;14(6):477-92 [11897488.001]
  • [Cites] Neoplasma. 2002;49(5):319-22 [12458330.001]
  • [Cites] Clin Cancer Res. 2003 Jan;9(1):355-62 [12538488.001]
  • [Cites] J Immunol. 2003 Feb 15;170(4):2004-13 [12574370.001]
  • [Cites] J Cell Biochem. 2003 Jun 1;89(3):484-99 [12761882.001]
  • [Cites] Proc Natl Acad Sci U S A. 1975 Sep;72(9):3666-70 [1103152.001]
  • [Cites] Recent Results Cancer Res. 1980;75:207-12 [7232833.001]
  • [Cites] J Immunol Methods. 1983 Dec 16;65(1-2):55-63 [6606682.001]
  • [Cites] J Immunol. 1984 May;132(5):2464-9 [6609199.001]
  • [Cites] Int J Cancer. 1984 Aug 15;34(2):263-7 [6469400.001]
  • [Cites] Cell Immunol. 1985 Jul;93(2):265-79 [3159480.001]
  • [Cites] Science. 1985 Nov 8;230(4726):630-2 [2413547.001]
  • [Cites] Science. 1985 Nov 22;230(4728):943-5 [3933111.001]
  • [Cites] Biochem Biophys Res Commun. 1986 Apr 14;136(1):94-101 [3486658.001]
  • [Cites] Proc Natl Acad Sci U S A. 1986 Jun;83(11):3949-53 [3520561.001]
  • [Cites] Biochem Biophys Res Commun. 1986 Jun 30;137(3):1094-100 [3015137.001]
  • [Cites] J Immunol. 1987 Jan 15;138(2):635-40 [3098851.001]
  • [Cites] Cancer Res. 1987 Feb 1;47(3):780-6 [3802082.001]
  • [Cites] J Immunol. 1987 Mar 1;138(5):1634-40 [3805727.001]
  • [Cites] Cancer Immunol Immunother. 1989;28(2):153-6 [2783890.001]
  • [Cites] J Biol Response Mod. 1989 Apr;8(2):206-18 [2499665.001]
  • [Cites] J Immunol. 1990 Feb 15;144(4):1425-31 [2303713.001]
  • [Cites] Cancer Immunol Immunother. 1990;31(1):19-27 [1968361.001]
  • [Cites] Acta Oncol. 1990;29(1):47-51 [2310603.001]
  • [Cites] Nature. 1990 Dec 6;348(6301):555-7 [1701033.001]
  • [Cites] Proc Natl Acad Sci U S A. 1991 Apr 1;88(7):2830-4 [1849278.001]
  • [Cites] Clin Exp Metastasis. 1991 Jan-Feb;9(1):57-65 [2015718.001]
  • [Cites] J Immunol. 1991 May 15;146(10):3682-6 [1673988.001]
  • [Cites] J Immunol. 1991 Dec 15;147(12):4398-401 [1684377.001]
  • [Cites] Clin Exp Metastasis. 1992 Mar;10(2):91-7 [1537138.001]
  • [Cites] Int J Cancer. 1993 Mar 12;53(5):829-36 [8449608.001]
  • [Cites] Lymphokine Cytokine Res. 1993 Dec;12(6):439-47 [8123760.001]
  • [Cites] Cytokine. 1993 Nov;5(6):546-55 [8186366.001]
  • [Cites] Oncology. 1994 Mar-Apr;51(2):142-53 [8196898.001]
  • [Cites] Cancer Res. 1994 Jun 15;54(12):3233-6 [7515767.001]
  • [Cites] Haemostasis. 1994 Mar-Apr;24(2):132-8 [7959361.001]
  • [Cites] Biochem Biophys Res Commun. 1994 Nov 15;204(3):1067-73 [7980579.001]
  • [Cites] Shock. 1995 Jan;3(1):1-12 [7850574.001]
  • [Cites] Circ Shock. 1994 Sep;44(1):9-13 [7704939.001]
  • (PMID = 17659374.001).
  • [ISSN] 0004-069X
  • [Journal-full-title] Archivum immunologiae et therapiae experimentalis
  • [ISO-abbreviation] Arch. Immunol. Ther. Exp. (Warsz.)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Cyclohexanes; 0 / Interleukin-6; 0 / Recombinant Proteins; 0 / Sesquiterpenes; 0 / Tumor Necrosis Factor-alpha; 129298-91-5 / O-(chloroacetylcarbamoyl)fumagillol
  • [Other-IDs] NLM/ PMC2766459
  •  go-up   go-down






Advertisement